wiener klinische wochenschrift The Central European Journal of Medicine Wien Klin Wochenschr (2015) 127:803–839 DOI 10.1007/s00508-015-0873-9 Online publiziert: 8. Oktober 2015 © Springer-Verlag Wien 2015

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie Graz, 15.–17. Oktober 2015

Abstracts Präsident: Univ.-Prof. Dr. Michael Studnicka Kongresssekretäre: Priv.-Doz. Dr. Bernd Lamprecht Dr. Romana Mikes Kongressorganisationskomitee (KOK): MR Dr. Kurt Aigner Dr. Wolfgang Auer Dr. Josef Bolitschek Univ.-Prof. Dr. Otto Chris Burghuber Dr. Peter Errhalt Dr. Andreas Fazekas Dr. Holger Flick Priv.-Doz. Dr. Georg-Christian Funk Dr. Anna Haider Dr. Sylvia Hartl Dr. Peter Hesse Dr. Maximilian Hochmair Priv.-Doz. Dr. Friedrich Horak Dr. Jörg Hutter

Dr. Eveline Kink Univ.-Prof. Dr. Meinhard Kneussl Priv.-Doz. Dr. Gabor Kovacs Priv.-Doz. Dr. Bernd Lamprecht Univ.-Prof. Dr. Horst Olschewski Dr. Otmar Schindler Dr. Wolfgang Schreiber Priv.-Doz. Dr. Ingrid Stelzmüller Dr. Heinrich Stolz Helmut Täubl, MScN Dr. Martin Trinker Dr. Karin Vonbank Marlies Wagner, MSc. Priv.-Doz. Dr. Angela Zacharasiewicz

.

abstracts

COPD mit Überraschungen P. Braz1, V. Hirzoiu1, U. Koller-Herzog1, J. Rappold2, G. Kühteubl1, M. Lachmann1, P. Schenk1  ulmologische Abteilung, Landesklinikum Hochegg, P Hochegg, Österreich 2 Neurologische Abteilung, Landesklinikum Hochegg, Hochegg, Österreich 1

Die 58-jährige Patientin mit hochgradiger COPD, respiratorischer Globalinsuffizienz mit nächtlicher nichtinvasiver Heimbeatmung wurde aufgrund deutlich erhöhter pCO2-Werte mit respiratorischer Azidose auf die Überwachungsstation aufgenommen. Unter intensivierter nichtinvasiver Beatmung waren die pCO2-Werte rasch rückläufig. Auffallend war aber, dass die Patientin über lange Phasen kontrolliert beatmet werden musste, trotz deutlich gebesserten pCO2-Werte war die Bewusstseinslage wechselnd. Am Aufnahmetag wurde eine Schädel-CT-Untersuchung veranlasst, welche als unauffällig befundet worden war. Nativradiologisch imponierte im Lungenröntgen eine Mediastinalverbreiterung nach rechts, diese stellte sich in der Thorax-CT-Aufnahme als ausgedehnte mediastinale Raumforderung dar. Aufgrund der anhaltenden neurologischen Einschränkung im Sinne einer allgemeinen Muskelschwäche, der Schluckbeschwerden, der bulbären Sprache, sowie des auffälligen Atemmusters in Zusammenschau mit der thorakalen Raumforderung wurde der Verdacht auf das Vorliegen eines Lambert-Eaton Syndroms geäußert. Noch unter nichtinvasiver Beatmung wurde eine Bronchoskopie durchgeführt, aus den entnommenen Nadelbiopsien konnte allerdings keine Diagnose gestellt werden. Mittels EBUS unter nichtinvasiver Beatmung gelang eine suffiziente Probeentnahme, sodass die Diagnose eines kleinzelligen Lungenkarzinoms gestellt werden konnte. Es wurde eine Therapie mit Mestinon und Cortison begonnen, wobei eine deutliche neurologische Verbesserung zu erkennen war. Nach respiratorischer und neurologischer Stabilisierung wurde der erste Chemotherapiezyklus verabreicht. Die Patientin konnte in deutlich gebessertem Allgemeinzustand nach Hause entlassen werden, die Chemotherapie wird fortgeführt.

F02 „A schiacha Huast’n...“ – und was dabei herauskommt H. Eisenberger Pulmologisches Zentrum, LKH Hörgas-Enzenbach, GratweinStraßengel, Österreich

Patientencharakteristik, Anamnese und Symptome:  69-jähriger, adipöser ehemaliger Raucher (kum. 50 py) mit Fieber, ständigem Husten und abendlichem Auswurf dunklen Blutes seit einer Woche. Keine Dyspnoe. Reduzierter Appetit. Psoriasis vulgaris unter Lokaltherapie. Anamnestisch erhobene Penicillinallergie. In der Vorgeschichte Abklärung bei Verdacht auf EAA im Jahr 2014. Damals Vd. auf IPF (CT-Thorax 2014). Im Status praesens außer Ent-

13

faltungsknistern bds. keine Auffälligkeiten. Vortherapie mit Moxifloxacin seit zwei Tagen. Diagnostik und Diagnose: Aufnahmeprofil inkl. Gerinnung, CRP, PCT, IGRA, Immunologisches Labor, Virusstatus; BGA, Konventionelles Thoraxröntgen, Fiberbronchoskopie mit DAH, Hautstanze aus Exanthem am Oberschenkel, CT des Thorax. Alternativ-, Differentialdiagnostik: Eine Gerinnungsstörung konnte mittels Labor ausgeschlossen werden. Ein Malignom war aufgrund der Vorbefunde mit CT-Thorax vor einem Jahr unwahrscheinlich. Ein toxischer Lungenschaden war anamnestisch nicht suspiziert worden. Therapie:  Ex juvantibus Methylprednisolon 1 g/d i.v. über drei Tage, anschließend prolongiertes Ausschleichen. Invasive Beatmung und Katecholamingabe wegen respiratorischen Versagens Kreislaufdepression; Hämodialyse aufgrund eines Nierenversagens; Antibiose mit Moxifloxacin, Meropenem, später Meropenem und Linezolid; antimykotische Abdeckung mit Caspofungin. Entnahme einer Hautstanze im Bereich eine Exanthems am Oberschenkel. Der histologische Befund bestätigt die Verdachtsdiagnose. Letztendliche Besserung des Zustandsbildes ohne neurologische Defizite. Mobilisierung und Transfer an die Rheumatologie LKH Graz. Dort Einleitung von Azathioprin. Literatur ERS Handbook: Respiratory medicine, 2nd edition: 402–408; 417 ff.

F03 Eine pulmonale Raumforderung ungewöhnlicher Genese A. Schuch, K. Patocka, W. Pohl Abteilung für Atemwegs- und Lungenkrankheiten, Krankenhaus Hietzing, Wien, Österreich

Eine initial eindrucksvolle – mit entsprechender Symptomatik klinisch hochsuspekt auf Malignität hinweisende Raumforderung – entpuppt sich als „ein Schaf im Wolfspelz“. Anfang Juni präsentiert sich ein 64-jähriger Patient (188  cm, 123 kg; Nieraucher, keine signifikanten Vorerkrankungen, in der Jugend längere Staubbelastung in der Rosshaarverarbeitung). Seit ca. 5 Wochen besteht eine progrediente Dyspnoe und sowie ausgeprägte B-Symptomatik, unproduktiver Husten sowie Schmerzen in den großen Gelenken (Knie und oberen Sprunggelenk) seit längerem. Ein rezenter Auslandsaufenthalt ist nicht erhebbar, ebenso keine Hautveränderungen. Mitte Mai hatte der Patient eine Pneumonie mit hohem Fieber, welche vom Hausarzt antibiotisch mit Ciproxin behandelt wurde. Laborchemisch kann h.o. ein gering erhöhtes CRP (15  mg/l) bei sonst blanden Parametern festgestellt werden. Der pulmonale Gasaustausch in Ruhe ergab eine nicht sauerstoffpflichtige respiratorische Partialinsuffizienz, die Lungenfunktion zeigt grenzwertige normale Lungenvolumina ohne Hinweis auf Obstruktion. Im Thoraxübersichtsröntgen imponiert ein deutlich plumper Hilus sowie Erguss links. Das Thorax-CT zeigt ein deutlich links vermindertes Lungenvolumen mit großer zentraler Raumforderung links hilär, zahlreichen vergrößerten mediastinalen Lymphknoten, sowie einem ca. 4 cm hoher Pleuraerguss links (Abbildung).

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

805

ÖGP

F01

ÖGIM

Fall des Jahres 2015

ÖGP

ÖGIM

abstracts

Zur weiteren Abklärung erfolgt eine Bronchoskopie mit EBUS (zahlreiche Nadel- und Zangenbiopsien sowie BAL) als auch eine Pleurapunktion. Bei guter Materialqualität zeigt sich jedoch kein Hinweis auf einen malignen Prozess. Eine Tumormarkeranalyse bleibt ebenfalls ohne signifikantes Ergebnis. Ein Schädel- und Abdomen-CT ist unauffällig. Es erfolgt eine ausführliche Labordiagnostik, mit u. a. Rheumatologie, Tbc Diagnostik, Virologie, spez. Proteindiagnostik, sowie ausgedehntem infektiologischem Screening inkl. Pilzinfektionen. Hier werden weitgehend unauffällige Parameter festgestellt, auffällig ist jedoch anfangs ein stark erhöhter CMV-AK-Titer. Aufgrund der protrahierten Symptomatik erfolgt eine virostatische Therapie mit Aciclovir über 14 Tage. Eine Thorax-CT-Kontrolle nach einem Monat zeigt einen regredierten Befund mit fast Komplettremission. Bei der Nachuntersuchung nach 1/2 Jahr konnten blande Befunde erhoben werden. Eine Immunschwäche, welche oft mit einer CMV induzierten Pneumonie einhergeht, konnte beim Patienten nicht festgestellt werden.

F04 „Vanishing bone“ – woher kommt so viel Erguss? P. Vinatzer1, B. Lang1, W. Fröhler2, H. Feizelmeier1, J. Eckmayr1  bteilung für Lungenkrankheiten, Klinikum Wels-Grieskirchen, WelsA Grieskirchen, Österreich 2 Institut für Radiologie I, Klinikum Wels-Grieskirchen, WelsGrieskirchen, Österreich 1

Anamnese:  Ein 35-jähriger Mann wurde aufgrund von beidseitigen Pleuraergüssen an unserer Abteilung vorstellig. Zwei Jahre zuvor war aufgrund von Thoraxschmerzen und Dyspnoe eine thorakale Computertomographie durchgeführt worden. Die dabei aufgefallene Veränderung im vorderen oberen Mediastinum mit zystischen Anteilen wurde zunächst als Mediastinitis interpretiert. In CT-Verlaufskontrollen zeigte sich eine Größenprogredienz. Im Anschluss an eine Mediastinoskopie erfolgte die Exstirpation der Raumforderung mittels partieller Sternotomie. Die histologische Untersuchung ergab einen Thymusrest mit perithymischen Lymphgefäßstrukturen.

Diagnostik:  Drei Monate später wurde erstmalig an unserer Abteilung eine Pleurapunktion durchgeführt. Es fand sich ein hämorrhagischer Erguss ohne Keimnachweis. Trotz antiinflammatorischer Therapie waren beidseits wiederholte Drainagen erforderlich. Bei jeweils nüchternem Patienten bestanden niedrige Triglicerid-Spiegel im Punktat, erst nach Provokation mit fettreicher Nahrung konnte ein Chylothorax diagnostiziert werden. Klinisch und radiologisch fielen im Verlauf Osteolysen im Bereich von Sternum, Clavicula und 1.–3. Rippe rechts auf. Dies legte die Verdachtsdiagnose GorhamStout-Syndrom nahe, die Bestätigung gelang mittels chirurgischer Weichteil- und Knochenbiopsie, wo sich die charakteristische lymphangiomatöse Proliferation mit Osteolyse zeigte. Diagnose:  Das Gorham-Stout-Syndrom, auch Vanishing bone disease, ist eine seltene Erkrankung charakterisiert durch diffuse Lymphgefäßproliferation begleitet von progressiver Knochenresorption. Die Ätiologie ist unklar. Alle Teile des Skeletts können betroffen sein. Die Symptome sind abhängig von der Lokalisation und können Schmerzen, Schwellungen und pathologische Frakturen umfassen. Bei thorakaler Manifestation kann es zum Auftreten eines Chylothorax kommen, was mit einer hohen Mortalität einhergeht. Betroffen sind vor allem Kinder und junge Erwachsene. Therapie:  Eine konservative Therapie des Chylothorax mit totaler parenteraler Ernährung bzw. einer Diät mit mittelkettigen Fettsäuren zeigte keinen Erfolg. Aufgrund der Seltenheit der Erkrankung ist keine Standardtherapie bekannt. Wie in Fallberichten beschrieben, wurde eine Therapie mit Bisphosphonaten und Calzium-D3 eingeleitet. Im Anschluss an eine thorakale Radiotherapie mit 40  Gy wurden Interferon a und Bevacizumab verabreicht. Bei steigender Frequenz der notwendigen Punktionen war die Anlage eines dauerhaften Pleurakatheters erforderlich. Schließlich wurde eine thorakoskopische Ligatur des Ductus thoracicus angestrebt.

F05 „Postoperativ nicht ganz dicht – untreatable airleak?“ M. Humenberger, R. Kropfmüller, J. Demmer, B. Lamprecht Abteilung für Pneumologie, Kepler Universitätsklinikum Linz, Linz, Österreich

Bei dem unsererseits präsentierten Fall handelt es sich um einen 35-jährigen Patienten, welcher uns im Juni dieses Jahres erstmals von Seiten der thoraxchirurgischen Abteilung unseres Hauses, mit der Bitte um interdisziplinäre Beurteilung einer Stumpfinsuffizienz bei Z. n. Pneumektomie links vorgestellt wurde. Anamnestisch musste der Patient 2013 aufgrund einer schweren Pleuropneumonie linksseitig mit Sepsis maschinell beatmet und intensivmedizinisch betreut werden. Im November 2013 wurde hinsichtlich eines zu suspizierenden Pleuraempyems DD Tumorverdacht eine 2-malige Thorakotomie durchgeführt, histologisch konnte neben einer abszedierenden und organisierenden Pneumonie kein malignes Geschehen nachgewiesen werden. Im Januar 2015 wurde der Patient mit dem Bild einer „destroyed lung“ links an der Thoraxchirurgie des AKH Linz aufgenommen und eine Pneumektomie links an der ECMO durchgeführt. Im weiteren Verlauf wurde im Mai 2015 eine Spätinsuffizienz des Bronchusstumpfes links diagnostiziert, und der Fall wurde uns chirurgischerseits mit der Bitte um endoskopische Sanierung des airleaks, als Alternative zur chirurgischen Intervention, präsentiert. An Symptomatik zeigen sich zu diesem Zeitpunkt ein chronischer Hustenreiz und eine zunehmende Ruhedyspnoe, begleitet von linksthorakalen Schmerzen. Eine COPD °III–IV ist vorbekannt, eine respiratorische Globalinsuffizienz ist vorliegend. Nach entsprechender endoskopischer Exploration, und trotz der zentralen Lage des air-leaks im Bronchialsystem wird nach

806   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

abstracts

F06 Radiatio – eine Gratwanderung C. Froschauer Abteilung für Pulmologie, LKH Steyr, Steyr, Österreich

Das Interesse an dem Fall liegt in der Einzigartigkeit der Komplikation. Patient:  Ein 58-jähriger männlicher Patient mit rezidivierendem Fieberanstieg, Nachtschweiß und Gewichtsverlust kommt mit auswärtigem Thorax-CT und dem Verdacht auf Lymphom zur Aufnahme. Es besteht ein Status post Nikotinabusus von ca. 40 packyears. Diagnostik/Diagnose:  Nachdem 2mal frustran versucht wurde, bronchoskopisch zu einem Ergebnis zu gelangen, wird schließlich mittels Mediastinoskopie die Diagnose eines großzelligen Karzinoms der Lunge mit Lymphknotenmetastasen gestellt (Abbildung). Therapie:  Nach 2 Zyklen Chemotherapie Pemetrexed/Carboplatin wird in Anlehnung an eine Studie der Universitäts-Klinik Salzburg (Erstveröffentlichung 2014) eine hyperfraktionierte, akzelerierte Radiotherapie mit Gesamtdosis bis 79,2  Gy durchgeführt. Postinterventionell entwickelt sich eine radiogene Ösophagusstenose, es folgen mehrere Bougierungen und Stentanlagen inklusive Revisionen. Im späteren Verlauf kommt es zu einer ösophagobronchialen Fistel und weiters zu einer großflächigen Auflösung der trachealen Pars membranacea sowie Teilen der Ösophaguswand. Literatur Strahlenther Onkol 2015;191(3):256–63. doi:10.1007/s00066-0140754-6

Multimodale Behandlung eines biphasischen Synovialsarkoms mit thorakaler Wirbelkörperinfiltration T. Klikovits1, M. Studnicka2, T. Brodowicz3, W. Klepetko1, R. Windhager4  linische Abteilung für Thoraxchirurgie, Medizinische Universität K Wien, Wien, Österreich 2 Universitätsklinik für Pneumologie, Universitätsklinikum Salzburg, Salzburg, Österreich 3 Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Wien, Österreich 4 Universitätsklinik für Orthopädie, Medizinische Universität Wien, Wien, Österreich 1

Patientencharakteristik, Anamnese und Symptome: Ein 26-jähriger männlicher Patient klagt seit 1,5 Jahren über progrediente Schmerzen im oberen Brustwirbelsäulen (BWS) Bereich. Er präsentiert sich in gutem Allgemein- und Ernährungszustand. Anamnestisch besteht ein St. p. Magenperforation bei Ulcus ventriculi, sonst keine weiteren Erkrankungen. Auf Grund von Persistenz der Schmerzen erfolgt eine weitere Abklärung. Diagnostik und Diagnose:  In der Computertomographie (CT) sowie Magnetresonanztomographie (MRT) des Thorax zeigt sich ein ausgedehnter 8,8 × 8,9 × 7,4  cm im Durchmesser haltender Tumor im rechten oberen Hemithorax mit Infiltration des Lungenapex, der dorsalen Rippen 1–3, der Brustwirbelkörper (BWK) 1–3 und Tumorausdehnung in die Neuroforamina Th 1–2 bis an den rechten Durasack. Der Tumor infiltriert das rechte obere Mediastinum mit Kompression von Vena und Arteria subclavia. Es erfolgt eine CT-gezielte Tumorbiopsie, welche das Vorliegen eines Synovialsarkoms ergibt. Eine ergänzende integrierte Positronenemisionstomographie (PET)/CT ergibt ein Stadium pT4 cN0 cM0. Therapie:  Nach interdisziplinärer Besprechung erfolgt eine konkomitante Induktionschemo-Radiotherapie mit 2 Zyklen Ifosfamid, welche vom Patienten gut toleriert wird. In der re-staging PET/ CT zeigt sich ein guter biologischer Response, weshalb eine schrittweise Resektion in kurativer Intention durchgeführt wird. Es erfolgt initial eine ventrale sowie transthorakale Mobilisation des Tumors mit extraanatomischer Segmentresektion des rechten Lungenapex, Resektion der Rippen 1–3 und eine dorsale Stabilisierung der WK C4 bis Th5. Auf Grund von starken Blutungen wird die Resektion unterbrochen und der Patient intubiert zur Stabilisierung auf die Intensivstation transferiert. Am Tag 1 erfolgt eine interventionelle Embolisation des Tumors und am Tag 8 die Resektion des Tumors mit en-bloc Vertebretektomie Th1 bis Th3 und dorsale Stabilisierung C4 bis Th5. Der postoperative Intensivaufenthalt beträgt 14 Tage. Der pathologische Befund ergibt das Vorliegen eines biphasischen Synovialsarkoms, im Gesunden entfernt. Der Patient wird postoperativ mobilisiert und am 60. postoperativen Tag in gutem AZ transferiert. Eine adjuvante Chemo- und Strahlentherapie ist in Planung. Literatur Seyhan EC, Sokucu SN, Gunluoglu G, Veske NS, Altin S. Primary pulmonary synovial sarcoma: a very rare presentation. Case Rep Pulmonol. 2014;2014:537618. doi:10.1155/2014/537618.

13

ÖGIM

F07

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

807

ÖGP

Rücksprache mit der Firma Olympus eine Implantation von zwei 9 mm Ventilen in den linken distalen Hauptbronchus durchgeführt. Postinterventionell ist in einer kurzfristigen endoskopischen Kontrolle, bei gutem Ergebnis und Verschluss des Stumpfes, bereits die Bildung von Granulationsgewebsbildung ersichtlich. So die Ventile, wie zu erwarten, in situ belassen werden können, würde dem Patienten derzeit nicht nur eine größere Operation erspart worden sein, sondern kann auch eine Ventilimplantation zentral im Bronchialsystem zum Verschluss eines postoperativen air-leaks als Therapiealternative herangezogen werden. Eine Verlaufskontrolle ist geplant. Die Implantation stellt an dieser Stelle des Bronchialssystems unserer Kenntnis nach ein absolutes Novum dar.

abstracts

ÖGP

ÖGIM

F08 Septische Granulomatose – ein Chamäleon: Tumor, Lungenfehlbildung oder Immundefekt? B. Kohlmaier1, H. Lackner1, M. Benesch1, A. Pfleger1, H. Till2, E. Sorantin3, P. Sovinz1, W. Schwinger1, K. Aubell5, M. de Boer7, D. Roos5, U. Demel4, D. Sperl1, V. Strenger1, R. Kerbl6, M. Seidel1, E. Eber1, Ch. Urban1  niversitätsklinik für Kinder- und Jugendheilkunde, Medizinische U Universität Graz, Graz, Österreich 2 Universitätsklinik für Kinder- und Jugendchirurgie, Medizinische Universität Graz, Graz, Österreich 3 Universitätsklinik für Radiologie, Medizinische Universität Graz, Graz, Österreich 4 Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich 5 Institut für Humangenetik, Medizinische Universität Graz, Graz, Österreich 6 Abteilung für Kinder und Jugendliche, LKH Hochsteiermark, Leoben, Österreich 7 Sanquin Blood Supply Foundation, Amsterdam, Niederlande 1

Grundlagen:  Die Abklärung intrapulmonaler Rundherde kann schwierig sein, muss jedoch rasch erfolgen. Methodik:  Ein 7 Wochen alter männlicher Säugling hatte rekurrierende respiratorische Infektionen, die unter oraler Antibiotikatherapie kontrollierbar waren und nur geringe Entzündungszeichen verursachten. Bildgebende Verfahren zeigten eine scharf, aber irregulär begrenzte links paravertebrale Raumforderung sowie mehrere Rundherde in beiden Lungen mit streifigen Ausläufern. Als Verdachtsdiagnosen wurden ein metastasierendes Neuroblastom sowie ein sekundär infizierter Lungensequester diskutiert. Ergebnisse:  Die Abklärung inkludierte BAL und Lungenbiopsie; letztere ergab eine umschriebene epitheloidzellig-granulomatöse Entzündung mit zentraler Nekrose und Pilzhyphen. Im Zuge der immunologischen Abklärung fand sich ein pathologischer Granulozytenfunktionstest mit einem um 99 % verminderten oxidativen Burst, sodass eine septische Granulomatose diagnostiziert wurde. Die molekulargenetische Analyse der neutrophilen Granulozyten zeigte eine fehlende Expression von pg91-phox, bestätigend für X-linked chronische granulomatöse Erkrankung (X-CGD). Unter Therapie mit einem Cephalosporin und Voriconazol über vier Monate kam es zu einer deutlichen Rückbildung der intrapulmonalen Herde. Vorbereitungen für eine Fremdspendertransplantation wurden eingeleitet. Beim 1 Jahr alten, asymptomatischen Bruder wurde ebenfalls eine CGD diagnostiziert. Schlussfolgerungen:  Zwischen Symptombeginn und Diagnose liegen bei CGD im Median 6 Jahre. Die einzige kurative Therapie ist die Stammzelltransplantation. Je nach Genotyp und Phänotyp können antibakterielle und antifungale Therapie auch lange Beschwerdefreiheit bewirken. Oft werden durch CGD entzündliche Darmerkrankungen oder auch hämophagozytische Lymphohistiozytose vorgetäuscht. In die Abklärung intrapulmonaler Rundherde muss schon im Säuglingsalter die seltene CGD einbezogen werden.

F09

Anamnese:  Ein 52-jähriger Patient wird mit dem Notarzt aufgrund von prolongierter Dyspnoe bei vorbekannter COPD ins Spital gebracht. Der Patient steht seit 6 Monaten in regelmäßiger Betreuung beim Lungenfacharzt, dabei ist es zu einem raschen Voranschreiten der spirometrisch gemessenen Obstruktion gekommen, sodass auch eine Mischform im Sinne eines ACOS in Differentialdiagnose genommen wurde. Eine kürzlich durchgeführte kardiologische Abklärung brachte keine wesentlichen Pathologien und der Patient wird bei Verdacht auf infektexazerbierte COPD stationär aufgenommen. Verlauf:  Aufgrund erhöhter Infektparameter und spastischen Atemgeräuschen wird eine Antibiose sowie Exazerbationstherapie begonnen. Dyspnoe-Beschwerden treten vor allem im Liegen auf, außerdem bestehen inspiratorische Nebengeräusche. Ein Trachealkollaps-Syndrom wird suspiziert und die Indikation zur bronchoskopischen Abklärung gestellt. Dabei findet sich ein beinahe die gesamte Zirkumferenz einnehmender polypöser Exophyt im unteren Drittel der Trachea. Dieser kann in toto abgetragen werden, die histologische Auswertung zeigt ein chondromatöses Hamartom. In der Computertomographie des Thorax und Abdomen finden sich keine weiteren Auffälligkeiten. Die Lungenfunktion nach Abtragung zeigt eine unauffällige Fluss-Volumskurve, die Oxygenierung ist im Normbereich, die bisherige „stadiengerechte COPD-Therapie“ kann beendet werden. Die Infektparameter und die Klinik einer scheinbaren Exazerbation sind einer poststenotischen Bronchitis zuzuschreiben, die Symptomatik bessert sich rasch und der Patient kann völlig beschwerdefrei entlassen werden. Schlussfolgerungen:  Lungenfunktionell ist eine ungewöhnliche Konfiguration der Fluss-Volums-Kurve ohne Peak oder typischen Emphysemknick erkennbar, wobei jedoch in der Inspirationsphase kein eindeutiges Plateau vorliegt. Die Resistance-Kurve zeigt einen ungewöhnlich, S-förmig imponierenden Verlauf. Aufgrund der gestielten Form des Hamartoms, das an der Vorderwand der distalen Trachea den Ursprung hatte, kam es vor allem im Liegen zu einer hochgradigen Obstruktion des Atemwegs. Zuletzt konnte auch ein inspiratorisches Nebengeräusch erhoben werden. Dies sollte jedenfalls Anlass zur weiteren Abklärung geben. Hamartome stellen die häufigsten benignen Lungentumore dar. 10 % finden sich endobronchial (und endotracheal), die restlichen 90 % intraparenchymal [1]. Tracheale Hamartome werden selten in der Literatur beschrieben, retrospektiv fanden sich lediglich ca. 20 Fallberichte in der PubMed Database seit 1959, die Inzidenz dürfte jedoch deutlich höher sein. Die Therapieoptionen umfassen waitand-see (bei gesicherter Histologie), chirurgische Sanierung, sowie die in erster Linie empfohlene endoskopische Resektion. Literatur 1. Irwin SR, Ernst A, Blackmon S, et al. Pulmonary hamartoma. In: Fraire EA, Cagle TP, Irwin SR, et al. (eds) Atlas of Neoplastic Pulmonary Disease. New York, NY, USA: Springer Science + Business Media, LLC; 2010, S.55–8.

F10 Schwere pulmonale Hypertonie bei schwerer Lungenkrankheit – eine therapeutische Herausforderung

Exazerbierte COPD, was sonst?

M. Kühnelt-Leddihn

K. Hackner1, J. Veres1, W. Riegler1, A. Varga2, P. Errhalt1

Klinische Abteilung für Lungenkrankheiten, LKH Universitätsklinikum Graz, New York, NY, USA, Österreich

 bteilung für Pneumologie, Universitätsklinik Krems a. d. Donau, A Krems a. d. Donau, Österreich 2 Abteilung für Pathologie, Universitätsklinik Krems a. d. Donau, Krems a. d. Donau, Österreich

71-jähriger Patient mit Belastungsdyspnoe seit 5 Jahren, 50 PY (zuletzt reduziert). Vorerkrankungen: COPD, monoklonale Gammopathie unklarer Signifikanz seit 1 Jahr.

1

808   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

1. Hoeper MM et al. Imatinib for pulmonary arterial hypertension.

Dtsch Med Wochenschr. 2014;139(Suppl 4):S151–4. 2. Ghofrani HA et al. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ 2015;5(2):296–304. 3. Speich R et al. Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension, Respiration 2015;89(6):515–24. 4. Hoeper MM et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127(10):1128–38.

F11 Gratwanderung zwischen Immunsupression und Malignomrisiko bei lungentransplantierten Patienten E. Haselwanter1, B. Bucher1, M. Stein1, A. Kreczy2, H. Jamnig1  bteilung für Pneumologie, LKH Hochzirl-Natters, Standort Natters, A Österreich Institut für Pathologie, Zytologie und Molekulare Diagnostik, Klinikum Coburg, Coburg, Deutschland

2

13

F12 Lungenkrank im Lungau: Alveolitis, ARDS oder anderes

Literatur

1

Frau W., eine 53-jährige, an COPD IV und Lungenemphysem erkrankte Patientin, wird im Jahr 2010 aufgrund der erwähnten Grunderkrankungen bilateral Lungen transplantiert. Der Verlauf nach Transplantation zeigt sich mit einer einmaligen CMV-Infektion im Transplantationsjahr, rezidivierenden akuten Abstoßungsreaktionen (A1–A2) in den Jahren 2011 und 2013 sowie den durch die Immunsuppression bedingten Nebenwirkungen (Osteoporose, CNV, arterielle Hypertonie) als nicht unüblich. Die immunsuppressive Therapie muss bei Frau W. aufgrund schon erwähnter Abstoßungsreaktionen und einer toxischen Neutropenie wiederholt umgestellt werden – Ende 2014 wird die Patientin mit Tacrolimus und Azathioprin behandelt. Anfang Dezember 2014 fällt bei einer Routinekontrolle im durchgeführten Thoraxröntgen erstmals eine Raumforderung rechts hilär auf. Die zytologische Aufarbeitung der bronchoskopisch mithilfe von endotrachealem Ultraschall entnommenen Lymphknotenaspirate ergibt das Bild einer pleomorphen post-transplant lymphoproliferative disorder (PTLD). Es folgt ein Ganzkörper-18 FDG-PET Scan zum Ausschluss weiterer pathologischer Herde. Darin zeigt sich eine multifokale stoffwechselaktive Lymphadenopathie im kaudalen Halsanteil beidseits als auch paraklavikulär, mediastinal rechtsbetont und des Lymphknoten rechts hilär. Somit ergibt sich im Staging ein Stadium II BE (Pulmo). Nach Implantation eines Port-A-Cath-Systems wird am 22.12.2014 die Chemotherapie mit R-COMP begonnen. Auf Grund toxischer Nebenwirkungen wird auf eine Monotherapie mit Rituximab reduziert. Trotz eines erhöhten Risikos für Abstoßungsreaktionen muss zur Sicherung des Therapieerfolges der PTLD die Immunsuppressionstherapie auf Tacrolimus und Prednisolon beschränkt werden. Derzeit befindet sich die Patientin in Vollremission und hat bis zur letzten Kontrolluntersuchung im Juli 2015 keine akute Abstoßung. Der Fall von Frau W. steht somit beispielhaft für die heikle Gratwanderung zwischen Immunsuppression und dem damit verbundenen erhöhten Malignomrisiko bei Patienten mit LUTX.

G. Rudelstorfer1, A. Lichtenschopf2, A. Studnicka-Benke3, I. Pretsch4, M. Studnicka1  niversitätsklinik für Pneumologie, Paracelsus Medizinische U Privatuniversität Salzburg, Salzburg, Österreich 2 Rehazentrum SKA Weyer, Weyer, Österreich 3 Universitätsklinik für Innere Medizin III, Rheumatologie, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Österreich 4 Universitätsklinik für Innere Medizin II, Kardiologie, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Österreich 1

Wir berichten über eine 50-jährige Patientin, die im Vorjahr an unserer Klinik vorstellig wurde. Anamnestisch war lediglich zu erheben, dass die Patientin einem möglicherweise inhalationstoxisch relevanten Hobby als Schnapsbrennerin nachging. Zum Zeitpunkt der Übernahme hatte die Patientin bereits einen mehrwöchigen beatmungspflichtigen Intensivaufenthalt unter dem klinischen Bild einer „fulminanten“ Pneumonie mit nachfolgendem ARDS hinter sich gebracht. Differentialdiagnostisch wurden die beidseitigen Lungeninfiltrate auch als Bronchiolitis obliterans oder exogen allergische Alveolitis gewertet, und es erfolgte u. a. eine Abklärung hinsichtlich CMV, HIV, Pneumocystis, Legionellen und Aspergillus. Im CTThorax wurden ausgeprägte Milchglasverschattungen beschrieben, teilweise mit dem Bild des crazy paving.

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

809

ÖGP

Auswärtige Befunde: Rechtsherzkatheter: mean PAP = 63 mmHg, PAWP = 7 mmHg, RAP = 12 mmHg, CI 2,7 L/Min/m2, PVR = 10,8 WE. Dünnschicht-CT: apikal betontes Lungenemphysem, basal geringe Zeichen der Fibrose. Echokardiographie: deutlich dilatierter und hypertophierter RV, SPAP = 110 mmHg, TAPSE = 13 mm, gut erhaltene linksventrikuläre Funktion, kein Perikarderguß. Bei Aufnahme Dyspnoe in der Ebene bereits bei geringem Tempo (NYHA III–IV) ohne thorakales Druckgefühl. Unter 2  L O2 pO2 46, pCO2 30,4  mmHg. Lungenfunktionsuntersuchung: FEV1 %FVC = 50 %, FEV1 = 63 % TLC = 111 %, DLCO = 18 % der Norm. Im EKG Sinustachykardie, Rechtstyp, inkompletter Rechtsschenkelblock. 6 mwd = 120 m. Unter Beibehaltung der bestehenden antiobstruktiven Therapie wurde eine Therapie mit Sildenafil eingeleitet. Drei Wochen später Exsikkose bei Diarrhoe mit prärenalem Nierenversagen und katecholaminpflichtiger Hypotension. Nach kardialer Rekompensation Umstellung auf Riociguat in einschleichender Dosierung. Nach zwei Monaten wurde versehentlich das Riociguat pausiert, und es kam zur katecholaminpflichtigen kardialen Dekompensation mit Multiorganversagen. Unter Fortsetzung von Riociguat Rekompensation auf niedrigem Niveau. Als ultima ratio zusätzlich Therapie mit Imatinib. Darunter allmähliche Stabilisierung des Krankheitsbildes: Anstieg der 6 mwd auf 226 m sowie Abnahme des Herzdurchmessers bei nur geringen Nebenwirkungen (geschwollene Tränensäcke, nicht transfusionsbedürftige Anämie mit Hb = 13,3 g%). Schlussfolgerungen:  Der Patient leidet laut Nizza Weltkonferenz 2013 an einer schweren PH-CPFE (combined pulmonary fibrosis with emphysema). Die Prognose ist sehr schlecht, limitierender Faktor ist meist ein Rechtsherzversagen. Es gibt für die PHCPFE derzeit keine explizite Therapieempfehlung. Die eingeleiteten Therapien mit PDE5i, Riociguat und Imatinib entsprechen jeweils einem klinischen Heilversuch. Hinweise auf die Wirksamkeit von PDE5i und Riociguat ergeben sich aus tierexperimentellen Daten (rauchende Maus). Hinweise für die Wirksamkeit von Imatinib ergeben sich aus tierexperimentellen Daten (Monocrotalin Ratte) und klinischen Phase II- und IIIDaten sowie Kohortenstudien. Nach unserer Kenntnis ist dies der erste Fall eines Patienten mit schwerer PH-CPFE, der mit der Kombination aus einem sGC-Stimulator (Riociguat) und einem Tyrosinkinase-Inhibitor (Imatinib) erfolgreich behandelt wurde.

ÖGIM

abstracts

ÖGP

ÖGIM

abstracts Zum Zeitpunkt der Entlassung von der Normalstation unserer Klinik war die Patientin mit einer oralen Steroidmedikation in absteigender Dosierung versorgt, und es erfolgte ein Transfer an das Rehabiliationszentrum Weyer. Nach wenigen Tagen des Rehab-Aufenthaltes kommt es erneut zur akuten klinischen Verschlechterung mit Zeichen der Hypoxämie und Lungeninfiltraten und wiederum Überweisung an unsere Klinik. Nun wurde dem Verdacht einer Lungenbeteiligung bei rheumatologischer Grunderkrankung nachgegangen und bei der Patientin ein Antisynthetase-Syndrom (Anti-Jo-1-Auto-AK pos.) mit Polymyositis und pulmonaler Beteiligung diagnostiziert. Nach Steigerung der Steroidmedikation kommt es wiederum zu klinischen Besserung der Patientin. In weiterer Folge wiederholte ambulante Begutachtungen und Einstellung auf unterschiedliche Immunsuppressiva. Zurzeit ist die Patientin unter einer Therapie mit Mycophenolat-Mofetil und Aprednisolon klinisch stabil. Im Retrospekt ist anzunehmen, dass bereits die intensivpflichtige, fulminante Pneumonie mit nachfolgendem ARDS die erste Manifestation des Antisynthetase-Syndroms war.

F13 Mimicking Sarkoidose M.-T. Mlczoch-Czerny, M. Hubner, M. Kneussl Medizinische Abteilung mit Pneumologie, Wilhelminenspital, Wien, Österreich

Anamnese:  62-jähriger Patient, guter Allgemeinzustand; anamnestisch Diabetes mellitus II mit oraler Therapie, Hepatitis C, arterielle Hypertonie. Symptome:  Zunehmende Belastungsdyspnoe führt zu einem CT-Thorax, in dem sich ausgeprägte mediastinale und hiläre Lymphknoten, sowie auch kleinnoduläre Veränderungen zeigen; abdominell finden sich nur marginal vergrößerte LK. Laborchemisch ist eine Niereninsuffizienz de novo (2,5 mg/dl), sowie auch eine Hypercalciämie (2,9  mmol/l) und ein erhöhter ACE-Spiegel (102 U/ml) auffällig. Diagnostik, Therapie und Verlauf: Bronchoskopie mit lymphozytärer BAL; typischer CD4/CD8 Ratio. Etablierung einer systemischen Corticoidtherapie 1  mg/kg/KG; nach kurzer Zeit Verbesserung der laborchemischen Parameter (Calcium, Kreatinin, ACE), der primär pathologischen Diffusionskapazität sowie schließlich auch des CT-Thorax im Sinne einer deutlichen Regressio der LK und der nodulären Parenchymveränderungen. Bei Reduzierung der Cortisontherapie kommt es nach Monaten wieder zur Verschlechterung des Calciumspiegels sowie des Kreatinins, jedoch zu keinem pulmonalen Relapse. Klinisch ist eine progrediente Gewichtsabnahme und Verschlechterung auffällig. In der CT-Kontrolle erscheinen ausgeprägte retroperitoneale Lymphknoten, sowie auch eine Raumforderung im Bereich der linken Nierenloge, von der Milz nicht abgrenzbar. Im PET finden sich intensiv speichernde pathologische hypermetabole Herde abdominell mit einem SUV von 25,0, sowie auch inguinal (SUV 21,3). Die Beckenkammbiopsie ergibt keinen Hinweis für eine lymphatische Erkrankung. Die Histologie eines inguinalen Lymphknotens bestätigt die Diagnose eines diffus großzelligen B-Zell Lymphoms. Der Patient wird mit einem chemotherapeutischem Schema nach R COMP therapiert und ist bei schlechtem Allgemeinzustand bereits seit vier Monaten hospitalisiert. Zusammenfassung:  Ein „klassischer“ Fall einer Sarkoidose mit durchwegs kompatiblen Befunden und primär gutem Ansprechen auf Cortison führte letztlich zur Diagnose eines B Zell Lymphoms. Es ist wahrscheinlich, dass es sich um eine sarkoide Reaktion der

Lunge im Rahmen der lymphatischen Erkrankung handelt, die sich zum Zeitpunkt der Diagnose zwei Jahre davor weder laborchemisch, noch radiologisch zeigte.

F14 „Die knöcherne Lunge“ – Diffuse pulmonale Ossifikation E. Kemetzhofer1 , C. Jarius2, A. Chott2, O. C. Burghuber1 I. Interne Lungenabteilung, Otto Wagner Spital, Wien, Österreich Pathologisch-bakteriologisches Institut, Otto Wagner Spital, Wien, Österreich

1

2

Anamnese:  Im Jahr 2004 wird ein vierzigjähriger, asymptomatischer, sportlicher Mann zur Abklärung einer mittels Lungenröntgen im Rahmen der Gesundenuntersuchung diagnostizierten interstitiellen Lungenstruktur-vermehrung an unserer Abteilung vorstellig. Im Status finden sich keinerlei Auffälligkeiten, auch eine ausführliche Anamnese ist bis auf die durchgemachten Kinderkrankheiten Masern, Mumps und Varizellen unauffällig. Weiterführende Diagnostik: Mittels Routinelabor, EKG und Blutgasanalyse (in Ruhe bei Raumluft) lassen sich keine Anomalitäten feststellen. In der Lungenfunktion zeigen sich grenzwertig normale Befunde mit Hinweis auf eine incipiente Diffusionsstörung (siehe Tab. 1). Die HRCT ergibt das Bild einer diffusen, interstitiellen retikulo-nodulären, teils punktförmig verkalkten Strukturvermehrung, vorwiegend um das bronchovaskuläre Bündel lokalisiert und von apical nach basal zunehmend – kein Milchglas, kein Honeycombing, unauffällige Lymphknoten, keine primär malignomsuspekten Veränderungen. Differentialdiagnostisch liegt zu diesem Zeitpunkt der Verdacht auf postpneumonische Veränderungen, beispielsweise im Rahmen der früheren Varizellen-Infektion, nahe. Letztlich liefert die diagnostische Bronchoskopie mit Biopsie aus dem rechten Unterlappen den entscheidenden Hinweis: in der histologischen Aufarbeitung kommt eine Lungengerüstvermehrung mit Knochenbildungsherden im Sinne einer diffusen, dendriformen Ossifikation zur Darstellung. Die zytolog. Aufarbeitung inkl. ZN und spezifischer Kultur aus der BAL ist unauffällig. Diagnose, Verlauf und Diskussion: Nach sorgfältigem Ausschluss sekundärer Ursachen diffuser pulmonaler Ossifikation wie chronische Lungen- oder Herzerkrankungen mit Druckerhöhung im kleinen Kreislauf, Autoimmunerkrankungen sowie Erkrankungen mit Störungen des Calcium-Phosphatstoffwechsels, wird schließlich eine idiopathische pulmonale Ossifikation diagnostiziert. Mit weniger als 50 Fallberichten in der weltweiten Literatur, stellt die idiopathische pulmonale Ossifikation ein äußerst seltenes Krankheitsbild dar, das vor allem Männer zwischen 40a und 60a betrifft und meist asymptomatisch bis mild verläuft. Nur in sehr ausgeprägten Fällen wurde lungenfunktionell eine restriktive Störung beschrieben. Die Diagnosestellung ist in vivo mittels HRCT, Lungenbiopsie oder Knochenszintigraphie möglich, zumeist wird die Erkrankung jedoch erst post mortem im Rahmen einer Autopsie als solche erkannt. Histologisch kann zwischen einem dendriformen und einem nodulären Typ unterschieden werden. Die Pathogenese ist nicht geklärt; vermutet werden Störungen im Calciumphosphatstoffwechsel, in der Angiogenese sowie Mikrotraumata. Therapeutisch gibt es keine evidenzbasierte Therapieempfehlung, die Gabe von Corticostereoiden und Biphosphonaten wird kontrovers diskutiert. Unser Patient zeigt nun seit >10a eine radiologische Befundkonstanz; lungenfunktionell lässt sich eine minimale Befundprogredienz feststellen (siehe Tab. 1). Subjektiv besteht nach wie vor Beschwerdefreiheit und der Patient benötigt keine Therapie.

810   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

abstracts

Tab.1  Lungenfunktion im Verlauf 2004–2014 FEV1

FEV1%/VC

Ist  %Soll

Ist  %Soll

 TLC Ist  %Soll

DLCOc

AaDO2 (70W 100W 200W)

 Ist   %Soll

5.08 81 %

3.72 72 %

72 89 %

7.35 87 %

11

5.03 84 %

3.24 66 %

64 77 %

7.35 90 %

8.76 72 %

87 %

10    21

 4

2014

4.78 81 %

3.26 68 %

68 82 %

7.27 88 %

8.78 72 %

20

30

37

ÖGP

2004 2009

ÖGIM

FVC Ist  %Soll

13

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

811

abstracts

ÖGP

ÖGIM

Poster Die mit einem * markierten Poster wurden in einem anonymisierten Review Verfahren als beste Poster ausgewählt.

P01

P02

Regional differences in lung vessel morphology from thoracic CT images*

Prognostic and clinical relevance of HSP expression in thymic epithelial tumors*

C. Payer1,2, M. Pienn1, M. Urschler2,3, G. Kovacs1,4, P. Douschan1,4, A. Olschewski1,5, H. Olschewski1,4, Z. Bálint1

S. Janik1,2, A. Schiefer3, C. Bekos2, P. Hacker1,2, W. Klepetko1, L. Müllauer3, H. J. Ankersmit1,2, B. Moser1

 udwig Boltzmann Institute for Lung Vascular Research, Graz, L Austria Institute for Computer Graphics & Vision, University of Technology, Graz, Austria 3 Ludwig Boltzmann Institute for Clinical-Forensic Imaging, Graz, Austria 4 Department of Pulmonology, Medical University of Graz, Graz, Austria 5 Department of Experimental Anaesthesiology, Medical University of Graz, Graz, Austria 1

2

Background:  The aim of this study was to analyze regional differences in the morphology of lung vessels in patients with and without pulmonary hypertension. We expected differences in vessel tortuosity depending on the analyzed lung region. Methods:  A fully automatic algorithm extracted the vessels from contrast-enhanced thoracic computed tomography (CT) images and labeled them as either arteries or veins. Regional differences in lung vessels were analyzed by filtering them with two sets of masks with equal volumes, which partition the lungs into bottom/middle/ top and back/middle/front, respectively. The vessel tortuosity was quantified with the distance metric (DM) and correlated with the mean pulmonary arterial pressure (mPAP) measured by right heart catheterization in a retrospective cohort of patients. Results:  Nineteen patients (5 without, 14 with PH) were analyzed retrospectively. There was no difference in the number of vessel segments in the different regions. Vessel tortuosity was increased in patients with PH (DMPH = 1.036 vs. DMnoPH = 1.029, p = 0.008). This difference was similar in the top and bottom thirds of the lung. In contrast, increased tortuosity could be observed in PH patients only in the back third (DMPH = 1.040 vs. DMnoPH = 1.029, p = 0.006), and not in the frontal part (DMPH = 1.034 vs. DMnoPH = 1.030, p = 0.06). The correlation of DM with mPAP was similar in each region (rtop = 0.72; rbottom = 0.70; rback = 0.71; rfront = 0.64 for all vessels). This correlation was similar in the arteries from the different regions (rtop = 0.69; rbottom = 0.65; rback = 0.74; rfront = 0.71), but lower in the respective veins (rtop = 0.62; rbottom = 0.50; rback = 0.49; rfront = 0.12). Conclusions:  Our fully automatic algorithm provides a regional readout of the arteries and veins from thoracic CT images. The power of the DM to distinguish PH, as well as its correlation with mPAP is uniform over the lung and originates from tortuous arteries. Therefore, tortuosity of the regional arteries may be a novel noninvasive tool to diagnose pulmonary hypertension.

 epartment of Thoracic Surgery, Medical University Vienna, Vienna, D Austria 2 Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration, Vienna, Vienna, Austria 3 Department of Pathology, Medical University Vienna, Vienna, Austria 1

Background:  Thymic Epithelial Tumors (TETs) comprising Thymomas, Thymic Carcinomas (TCs) and thymic neuroendocrine tumors (TNETs) are the most common tumors in the anterior mediastinum in adults. Heat shock proteins (HSPs) functioning as intracellular chaperones and inhibitors of apoptosis are overexpressed in several malignancies and correlated with tumor cell survival and poor clinical outcome. We aimed to investigate the prognostic and clinical relevance of the strongest inducible HSPs (HSP27&70) in serum and tissues specimens of patients with TETs. Methods:  Tissues specimens of 101 TETs were evaluated for HSP27 and 70 expression by immunohistochemistry and correlated with Masaoka Koga Tumor Stage, WHO tumor classification, overall survival (OS) and freedom from recurrence (FFR) rates. Additionally HSP27 and 70 serum concentrations were measured in patients with TETs (n = 46), thymic hyperplasia (TH; n = 33) and volunteers (n = 49). Moreover HSP27 serum levels (n = 16) were evaluated before and after resection. Results:  Strong cytoplasmic HSP27 and nuclear 70 expression was found in all TETs, except TNETs (p < 0.001 and p = 0.003, respectively). The strongest cytoplasmic and nuclear HSP70 expression was found in early tumor stages (Masaoka Koga stage I) and gradually decreased with increasing malignant tumor behavior (p = 0.261 and p = 0.037, respectively). Lowest HSP70 expression was found in metastatic tumors. FFR was significantly worse in TETs with absent or low cytoplasmic HSP27 and nuclear HSP70 expression (p = 0.017 and p = 0.016, respectively). Serum HSP27 and 70 concentrations were increased in patients with TETs (p = 0.040 and p = 0.021, respectively), particularly in patients with TCs (p = 0.027 and p = 0.034, respectively). HSP27 serum concentrations significantly decreased after complete tumor resection (p = 0.015). Conclusions:  TETs generally overexpress HSP, except TNETs. Low HSP expression in tumor specimens was associated with worse FFR. Serum HSP concentrations were elevated in patients with TETs, advanced tumor stages and decreased after complete tumor resection.

812   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

abstracts

P04 A randomized, double-blind, cross-over trial of supplemental oxygen for exercise training in normoxemic COPD*

V. Laszlo1, J. Ozsvar1, M. A. Hoda1, T. Klikovits1, W. Berger2, M. Grusch2, W. Klepetko1, F. Hilberg3, B. Dome1,4,5, B. Hegedus1,6

D. Neunhäuserer1,3, E. Steidle-Kloc1,5, G. Weiss2, B. Kaiser2, D. Niederseer1*, S. Hartl6, M. Schönfelder1, B. Lamprecht2,4, M. Studnicka2, J. Niebauer1

 ivision of Thoracic Surgery, Department of Surgery, Comprehensive D Cancer Centre Vienna, Medical University Vienna, Vienna, Austria 2 Institute of Cancer Research, Department of Internal Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 3 Boehringer Ingelheim Austria GmbH, Vienna, Austria 4 National Koranyi Institute of Pulmonology, Budapest, Hungary 5 Department of Thoracic Surgery, National Institute of Oncology, Semmelweis University, Budapest, Hungary 6 Tumor Progression Research Group, Hungarian Academy of Sciences-Semmelweis University, Budapest, Hungary

1

1

Background:  Malignant pleural mesothelioma (MPM) is a devastating malignancy with still rising incidence worldwide. Currently, platinum-based chemotherapy in combination with antifolate agents is the standard front-line therapy for MPM and to date no molecularly targeted therapeutic approaches have been approved in the clinics. Nintedanib, an inhibitor of VEGFR, PDGFR and FGFR tyrosine kinase isoforms, is capable to suppress angiogenesis and tumor growth. Here, we report the antitumor activity of nintedanib in MPM. Methods:  IC50 values for nintedanib were determined in 21 MPM cell lines. 4 cell models were selected for further in vitro analysis: proliferation, apoptosis, colony formation and cell migration assays were performed. The downstream signaling of the target receptors was investigated by immunoblotting. Drug interactions with cisplatin were assessed by using the CalcuSyn software. The in vivo anti-MPM activity of nintedanib was studied in an orthotopic human MPM xenograft model in SCID mice. Results:  Nintedanib exerted a growth inhibitory effect on MPM cell lines in both short- and long-term viability assays. The inhibition of proliferation was observed in all MPM cell models, whereas significant apoptosis induction was only found in half of them. Migratory activity strongly decreased upon nintedanib treatment. Down-regulation of Erk1/2 phosphorylation was evident within 10  min of treatment and was present even after 24  h. Nintedanib, however, had no inhibitory effect on the activation of Akt or S6. Additive, but no synergistic effect with cisplatin was detected. In vivo, survival of PO-treated animals showed favorable trend, but not significant benefit (vs. PO control, log-rank test, p = 0.059). However, nintedanib significantly prolonged the survival of mice when it was administered IP (vs. IP control, log-rank test, p = 0.0008). Conclusions:  Our data suggest that nintedanib exerts antitumor activity in MPM both in vitro and in vivo and thus may represent a promising novel therapeutic option in this malignancy.

13

ÖGIM

Nintedanib exerts migration and proliferation inhibition in malignant pleural mesothelioma cells in vitro and prolongs survival in an orthotopic xenograft model*

 niversity Institute of Sports Medicine, Prevention and U Rehabilitation, Paracelsus Private Medical University Salzburg, Salzburg, Austria 2 University Clinic of Pneumology, Paracelsus Privat Medical University Salzburg, Salzburg, Austria 3 Sport and Exercise Medicine Division, Department of Medicine, University of Padova, Padova, Italy 4 Kepler-University-Hospital, Department of Pulmonary Medicine, Johannes-Kepler-University, Faculty of Medicine, Linz, Austria 5 Institute of Anatomy, Paracelsus Private Medical University Salzburg, Salzburg, Austria 6 First Internal Department of Pulmonary Medicine, Otto-WagnerSpital, Vienna, Austria *Current Author’s address: Division of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland

Background:  Physical exercise training is an evidence-based treatment in COPD and patients’ maximal work capacity is strongly associated with COPD mortality. What remains unknown is whether normoxemic COPD patients benefit from supplemental oxygen during exercise training. Methods:  The Salzburg COPD Exercise and Oxygen (SCOPE) study is a randomized, double-blind, controlled, cross-over trial in 29 normoxemic COPD patients (63.5 ± 5.9 years; FEV1%pred.: 46.4 ± 8.6). Participants completed two consecutive periods of 6 weeks of endurance and strength training with progressive intensity, which was performed three times/week with either supplemental oxygen or pressurized room-air (10  l/min, via nasal cannula). Each session of ECG-controlled interval cycling lasted 31 min and consisted of warm-up, seven cycles of one-minute intervals at 70–80 % of maximal work capacity alternating with two minutes of active recovery, and cool-down. Thereafter, participants completed eight strength training exercises, performing one set with 8–15 repetitions to failure. Change in maximal work capacity was the primary study endpoint. Secondary outcomes were further parameters of exercise capacity, muscle strength and the Hospital Anxiety and Depression Scale. Results:  The increase in maximal work capacity was more than twice as high when patients exercised with supplemental oxygen as compared to room-air (+ 0.16 ± 0.02 vs. + 0.07 ± 0.02 Watt/kg; p < 0.001), which was consistent with all other secondary study endpoints related to exercise capacity. The impact of oxygen on work capacity was 39.1 % of the overall training effect, whereas it had no influence on strength gain (e.g. 10-RM latissimus pull-down; p = 0.428) or depression (p = 0.341). For anxiety a trend for a beneficial oxygen effect was observed (−17.48 %; p = 0.084). Conclusions:  We demonstrate for the first time that supplemental oxygen in normoxemic COPD doubles the effect of endurance training, but has no effect on strength gain. A more rapidly increased work capacity might lead to better compliance with training prescriptions, which would thus revolutionize out-patient COPD therapy.

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

813

ÖGP

P03

abstracts

ÖGP

ÖGIM

P05 Ex-vivo lung perfusion of standard donor lungs prior to transplantation: a prospective randomized trial* A. Slama, M. Barta, L. Schillab, A. Mitterbauer, K. Hoetzenecker, S. Taghavi, G. Lang, P. Jaksch, W. Klepetko, C. Aigner Medical University of Vienna, Vienna, Austria

Background:  Even though the benefits of EVLP with marginal donor lungs have been previously demonstrated, there were no investigations to show if standard donor lungs could benefit of EVLP too. Aim of this study was to investigate the difference in the patient’s outcome between cold storage and normothermic ex vivo lung perfusion (EVLP) prior to lung transplantation (LuTX). Methods:  In this prospective randomized single center study two groups of patients were compared to each other. Donor lungs in Group A were subjected to 4  h of normothermic EVLP according to our standard protocol before they were assessed and transplanted. Lungs in Group B were directly transplanted after standard cold storage. Recipient inclusion criteria were: primary LuTX; age > 18j; absence of primary pulmonary hypertension, no preoperative bridging. From October 2013 to Mai 2015, 80 pairs of eligible recipients and their allocated donor lungs were randomized (group A EVLP: n = 39; group B control: n = 41). Within the perfused lungs, decision to transplant was withdrawn during EVLP in 4 cases due to insufficient quality (n = 2), vascular anomalies (n = 1) and iatrogenic damage during retrieval (n = 1), leading to 35 subsequently transplanted lungs. Results:  Recipient and donor demographics were comparable in all means. Post-operative outcomes were comparable in terms of: Intubation time (1.4 vs. 1.6 days; p = 0.67), duration on ICU (6 vs. 6.4 days; p = 0.76) and hospitalization time (21.5 vs. 19 days; p = 0.55). The need for prolonged ECMO after LuTX such as 30d mortality was comparable for both groups (6.3 % vs. 13.9 %//2.9 % vs. 0 %). Neither oxygenation (at Fio2 = 1.0) nor occurrence of primary graft dysfunction (PGD > 1) did differ significantly (T24: 516 vs. 506 mmHG; p = 0.73//T72: 403 vs. 452 mmHG; p = 0.74//3.1 % vs. 2.8 % PGD; p = 0.29). Conclusions:  Short term outcomes were comparable in both groups. EVLP made it possible to safely detect previously unrecognized impairments of the donor lungs. Further, the preservation time was significantly prolonged.

P06

Methods:  238 subjects with respiratory diseases passed the pretest and 175 of them finished the posttest during an outpatient rehabilitation treatment. To predict health-related quality of life the chronic respiratory questionnaire (CRQ) [3] was used. The maximum endurance capacity was determined during a cycle ergometry with level protocol (Pmax). Furthermore, the difference between the post- to pretest values in CRQ and Pmax was calculated (diffCRQ bzw. diffPmax: posttest—pretest). Correlations between CRQ and Pmax were calculated in the pre- and posttest values as well as between diffCRQ and diffPmax. Results:  Correlation calculations of the pretest (preCRQ and prePmax) showed a highly significant relationship between maximum physical capacity and subjective quality of life (p < 0.001, r = 0.224). A higher correlation was presented in the posttest (postCRQ and postPmax) with the same significance (p < 0.001, r = 0.396). In addition the correlations of the difference variable (diffCRQ and diffPmax) were highly significant (p < 0.001, r = 0.320) Conclusions:  The maximum endurance capacity shows a highly significant relation with health related quality of life in respiratory patients and vice versa. An increase in the maximum endurance capacity leads to a significantly correlative improvement in quality of life. To summarize, improving the endurance capacity of respiratory patients is not only important for clinical recovery, but also likely affects the subjective well-being in a positive way. References 1. Altenburg W, Bossenbroek L, de Greef M, Kerstjens H, ten Hacken N, Wempe J. Functional and psychological variables both affect daily physical activity in COPD: a structural equations model. Respiratory Medicine. 2013;(107)11:1740–7. 2. Monteagudo M, Rodríguez-Blanco T, Llagostera M, Valero C, Bayona X, Ferrer M, Miravitlles M. Factors associated with changes in quality of life of COPD patients: a prospective study in primary care. Respiratory Medicine. 2013;(107)10:1589–7. 3. Guyatt G, Berman L, Townsend M, Pugsley S, Chambers L. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;(42):773–8

P07 The biological and clinical significance of alpha-1 antitrypsin in non-small cell lung cancer A. Szpechcinski1, J. Chorostowska-Wynimko1, R. Langfort2, E. Debek1, W. Kupis3, P. Rudzinski3, J. Zaleska4, B. Poplawska-Wisniewska1, T. Orlowski3, K. Roszkowski-Sliz4  ept. Genetics and Clinical Immunology, Institute of Tuberculosis D and Lung Diseases, Warsaw, Poland Department of Pathomorphology, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland 3 Department of Thoracic Surgery, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland 4 IIIrd Department of Lung Diseases, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland 1

Relationship between health-related quality of life and maximum endurance capacity in respiratory patients* A. Frühauf, P. Krüsmann, C. Puelacher Rehamed Tirol, Innsbruck, Austria

Background:  Psychological well-being influences daily physical activity in patients with COPD [1]. The aim of each rehabilitation center is the improvement of quality of life for the patients. A completed rehabilitation programme, quitting smoking and a balanced diet are factors that improve quality of life in patients with COPD [2]. The Relation between the maximum endurance capacity and the subjective health-related quality of life has not been evaluated yet in respiratory patients.

2

Abstract withdrawn

814   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

Smoking status of Austrian physicians (general practicioners and specialists) V. Kemmetinger, M. Neuberger, L. Awender, J. Forster, M. Hasanovic, V. Lobschat, J. Macinkovic, M. Mitterer, C. Müller, R. DeJonge Institute of Environmental Health, Center of Public Health, Medical University of Vienna, Vienna, Austria

Backgound:  The smoking status of physicians can influence the smoking prevalence of the general population. Many patients see their doctor as a role model for a healthy life style. Physicians, who smoke themselves, are less likely to recommend cessation programs to their patients. The intention of this survey was to analyze for the first time, whether there is a difference between the smoking habits of Austrian’s physicians and the general population. Methods:  A random sample of all practicing physicians was drawn in each province, stratified for specialty. From each specialty at least 10 % were surveyed by standardized telephone interview. Sensitivity analyses were performed for non-responders. Results were compared with the smoking status in the general population of the province (Health Interview Survey by Statistics Austria), adjusted for sex and age. Results:  The response rate in the 9 counties varied from 99 % (K, N, St, T, V, W) to 100 % (B, O, S). Non-smokers ranged from 84 % (B, W) to 94 % (S), consisting of never-smokers (B 48 %, K 70 %) and exsmokers (K 21 %, B 36 %).The quit rate was lowest in V (59 %) and highest in T (74 %). Current smokers ranged from 9 % (K, S, T) to 16 % (B, W). In all 9 provinces physicians smoked less than the general population corresponding in age and sex (expected smoking rates from 20 % in St to 35 in O). Except for B the differences between the smoking rates of physicians and the expected smoking rates in the age/sex-corresponding population was statistically significant. The lowest smoking rates were found in pneumologists and the highest in surgeons. Conclusions:  Even though the smoking prevalence of Austrian physicians is lower compared to physicians in Southern Europe, there is still a huge potential to decrease smoking prevalence in order to optimize the consultation of smoking patients.

P09 Denoising algorithm for quantitative assessment of thoracic dual-energy computed tomography images M. Pienn1, K. Bredies2, R. Stollberger3, G. Kovacs1,4, A. Olschewski1,5, H. Olschewski1,4, Z. Bálint1  udwig Boltzmann Institute for Lung Vascular Research, Graz, L Austria 2 Institute forMathematics and Scientific Computing, University of Graz, Austria 3 Institute of Medical Engineering, University of Technology, Graz, Austria 4 Departmentof Pulmonology, Medical University of Graz, Graz, Austria 5 Department of Experimental Anaesthesiology, Medical University of Graz, Graz, Austria 1

Background:  Dual-energy computed tomography (DE-CT) allows the visualization of perfusion defects in the lung and can therefore aid the diagnosis of acute or chronic pulmonary embolism. However, the contrast-to-noise ratio of the scanner-provided

13

images is too low for quantitative analysis of contrast material concentrations in the lung parenchyma. Methods:  We applied a 3D total generalized variation algorithm to denoise DE-CT images acquired with a Siemens Somatom Definition Flash scanner. The two X-ray source/detector systems were set to 100 kV/91 mAs and 140 kV/77 mAs with a 0.4 mm tin filter, respectively. For validation of the algorithm we used either images from a phantom experiment (Falcon tubes filled with different concentrations of iodine) or dynamic CT images of contras-material bolus propagation in 20 patients underwent thoracic CT examination. Results:  The algorithm denoised the images while preserving the anatomical information. Iodine concentrations determined with our algorithm and actual concentrations in the samples of the phantom experiment showed a linear correlation with a slope of 1 (R2 = 0.983) within the physiologic range of iodine between 0 and 20  mg/mL. The contrast-to-noise ratio was improved to values above 5 even in the low-concentration range (3.7  mg/mL). This allows reliable quantification of the expected iodine concentrations in the lung parenchyma, too. Dynamic CT images showed that X-ray attenuation values were not affected by the algorithm and, therefore, lead to almost identical results between the original and denoised datasets. This was further confirmed by assessing secondary parameters from the dynamic CT, like the cardiac output (Bland-Altmann test: difference − 0.03  L/min with confidence intervals: [− 0.37, 0.31] L/min). Conclusions:  3D denoising with the total generalized variation algorithm increases contrast-to-noise ratio while preserving anatomic structures and X-ray attenuation values. Therefore, this algorithm is suitable for the quantification of perfusion in thoracic dual-energy CT images. Validating the algorithm in a clinical setting of lung disease diagnosis is warranted.

P10 Scientific papers in the social media A. Konstantiniuk, K. Amrein Department of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Background:  Sepsis has a higher mortality than lung or breast cancer [1]. One of the most important etiologic factors is pneumonia [2]. Increasingly, social media play an important role to promote scientific work. To date, approximately one in four physicians uses social media to stay up-to-date on medical innovations and information [3]. However, scientific papers with a high impact in the social media may not necessarily represent high scientific quality but entertainment, controversity or abstrusity [4] such as studies on chocolate, weight loss or sexual activities. Methods:  Quantitative data about twelve important studies was collected. We compared four studies about early-goal directed therapy (EGDT) in sepsis with eight alternative major ICU studies analysing Twitter, Altmetrics, ResearchGate, Google Scholar and Web of Science. Results:  Sepsis studies had a higher social media representation in comparison to the other ICU studies. The ProCESS study (2014) had the highest Altmetrics score of all examined studies. The ARISE study (2014) even has a Twitter Account. Although the original EGDT trial [5] has been published fourteen years ago, it had an above average Altmetrics score (orginial EGDT = 176 vs average = 80.42). Interestingly, the Altmetric Score neither correlated with Google Citations (r = - 0.001, p = 0.998) nor publishing date (r = 0.022, p = 0.945). Conclusions:  We show that major sepsis studies have a high impact in the social media. The results suggest no significant corre-

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

815

ÖGP

P08

ÖGIM

abstracts

abstracts

ÖGP

ÖGIM

lation between publishing date and the impact in the social media. Future trials may assess the impact of the first author’s usage of social media on the success of the study in the social media.

cancer cells in a glucose-deprived microenvironment to fuel biosynthetic reactions usually fed by glycolytic intermediates.

References 1. Davies A. OECD health data, 2001.

2.  Daniels R., ABC of Sepsis, 2010. 3.  McGowan BS. Understanding the factors that influence the adoption and meaningful use of social media by physicians to share medical information, 2012. 4.  Crotty D. Altmetric’s Top 100: What does it all mean? 2014. 5.  Rivers E. Early goal-directed therapy in the treatment of severe sepsis and septic shock, 2001.

P12 Exercise-induced bronchoconstriction and cytokine changes in non-professional marathon runners C. Bekos1, S. Janik1, J. Didcock1, J. Kliman1, M. Koller3, R. Fritz3, C. Gäbler3, W. Klepetko2, H. J. Ankersmit1,2, B. Moser1,2  hristian Doppler Laboratory for the Diagnosis and Regeneration C of Cardiac and Thoracic Diseases, Medical University of Vienna, Vienna, Austria 2 Department of Thoracic Surgery, Division of Surgery, Medical University of Vienna, Vienna, Austria 3 Sportordination, Vienna, Austria 1

P11 Beyond Warburg effect: Adaptation to low glucose involves use of glutamine as alternative carbon source in lung cancer cells K. Leithner1, A. Hrzenjak1,4, M. Trötzmüller2, H. C. Köfeler2, A. L. Harris3, A. Olschewski4, H. Olschewski1  ivision of Pulmonology, Department of Internal Medicine, Medical D University of Graz, Graz, Austria 2 Core Facility Mass Spectrometry and Lipidomics, CMR, Medical University of Graz, Graz, Austria 3 Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK 4 Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria 1

Background:  Cancer cell adaptation to glucose deprivation, although frequently present in solid cancers, is poorly understood. Gluconeogenesis, the generation of glucose from small carbon substrates, is an important metabolic pathway in liver cells. Phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme for gluconeogenesis, and abbreviated pathways like glyceroneogenesis (generation of glycerol). We have shown that PEPCK (PCK2) is up-regulated in nonsmall cell lung cancer (NSCLC) cells under low glucose conditions. The aim of this study was to analyze, whether glutamine is a precursor for the gluconeogenesis pathway in lung cancer cells. Methods:  Expression of glutamine transporters and PCK2 was measured by quantitative PCR (qPCR). Conversion of uniformly 13 C-labeled glutamine or uniformly 13C-labeled lactate to the PEPCK product 13C3-phosphoenolpyruvate (PEP) was measured using liquid chromatography/mass spectrometry. Results:  The glutamine transporters SLC1A5 and SLC7A1 were up-regulated along with PCK2 in A549 lung cancer cells under low glucose conditions. Likewise, SLC1A5 and SLC7A1 expression positively correlated with PCK2 in a publically available dataset involving 967 cancer cell lines. In A549 lung cancer cells cultured under low glucose (1  mM), stable isotope labeled glutamine was converted to PEP. The accumulation of labeled PEP was significantly inhibited in the presence of the PEPCK inhibitor 3-MP was significantly higher under low glucose conditions as compared to high glucose conditions. The maximal ratio labeled/unlabeled PEP (app. 0.17) was observed at 0.2 mM glucose indicating that besides glutamine other carbon sources contribute to PEP, either from glycolysis, or gluconeogenesis. In fact, lactate carbons contributed to the PEP pool. Conclusions:  These results suggest that glutamine is converted to PEP via PEPCK under low glucose conditions in lung cancer cells. Glutamine thus may serve as an alternative carbon source in lung

Background:  Exercise is the most common trigger of bronchospasm. If exercise is the only identifiable trigger for the bronchoconstriction, it is called exercise induced bronchoconstriction (EIB), with an estimated prevalence of 8–20 % in the non-asthmatic population. We sought to investigate cytokine changes in non-professional marathon and half marathoners with and without EIB. Methods:  We enrolled 34 probands running a marathon (M), 36 running a half-marathon (HM) and 30 sedentary subjects without asthma. We employed immunosorbent assays to determine the serum concentration of heat shock protein (HSP) 70 and performed blood count analysis before the marathon (prerun), immediately post-marathon at the finish area (immediately after), and 2–7 days after the marathon (recovery). A spirometry was performed by a portable lung function testing device to assess FVC %, FEV1 % and the FEV1/FVC ratio. Results:  We found signs of EIB, defined as a decrease of ≥ 10 % in FEV1 from baseline, in 12 (35.29 %) marathon and 8 (22.22 %) half marathon runners. Among athletes with EIB, 11/20 (55 %) were male and 9/20 (45 %) were female. After distributing runners in a group with EIB and without EIB, we found significantly higher HSP70 serum concentrations in runners with EIB on the day before the competition (p = 0.014). After analyzing marathoners and half marathoners separately, we found significantly increased WBC in marathoners suffering from EIB before participating in the competition (p = 0.021). Immediately after the race we couldn’t detect any cytokine changes between runners with and without EIB. After 2–7 days of recovery we found significantly increased HSP70 serum concentrations (p = 0.032), WBC (p = 0.048) and PLT (p = 0.040) in marathoners with EIB, when compared to marathoners without EIB. Conclusions:  We found a higher than expected number of nonprofessional athletes with EIB. HSP70 serum concentrations and elevated WBC could indicate a predisposition to EIB.

P13 Histone deacetylase inhibitor panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1a destabilization C. Fischer1,2, K. Leithner1, C. Wohlkoenig1, F. Quehenberger3, A. Bertsch1, A. Olschewski4, H. Olschewski1, A. Hrzenjak1,4  ivision of Pulmonology, Department of Internal Medicine, Medical D University of Graz, Graz, Austria

1

816   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

Background:  Lung cancer is one of the most frequent cancer types and the leading cause of cancer death worldwide. Cisplatin is a widely used chemotherapeutic for non-small cell lung carcinoma (NSCLC), however, its positive effects are diminished under hypoxia. We wanted to determine if co-treatment with cisplatin and histone deacetalyse (HDAC) inhibitor panobinostat can reduce hypoxia-induced cisplatin resistance in NSCLC cells, and to elucidate mechanism involved. Methods:  Expression status of different HDACS was determined in two cell lines and in tumor tissue from 20 patients. Cells were treated with cisplatin, panobinostat, or with combination of both under normoxic and hypoxic (1 % O2) conditions. Cell cycle, viability, acetylation of histones, and activation of apoptosis were determined. Human primary, non-malignant bronchial epithelial (BE) cells were used as a control. HIF-1a stability was analyzed by immunoblotting and its interaction with HDAC4 was determined by in vitro proximity ligation. Results:  Most class I and II HDACs were expressed in NSCLC cells and tumor samples. Panobinostat inhibited proliferation of tumor cells under normoxic and hypoxic conditions. Co-treatment of tumor cells with cisplatin and panobinostat decreased cell viability and increased apoptosis more efficiently than in primary, nonmalignant bronchial epithelial cells. Co-treatment induced apoptosis by causing chromatin fragmentation, activation of caspases-3 and 7 and PARP cleavage. Toxic effects were more pronounced under hypoxic conditions. Co-treatment inhibited growth of multicellular-spheroids, where hypoxic conditions develop spontaneously because of limited oxygen diffusion. Co-treatment resulted in destabilization and degradation of HIF-1a and HDAC4, a protein responsible for acetylation and de/stabilization of HIF-1a. Direct interaction between HDAC4 and HIF-1a proteins in H23 cells was detected. Conclusions:  Here we show that hypoxia-induced cisplatin resistance can be overcome by combining cisplatin with panobinostat, a potent HDAC inhibitor. These findings may contribute to the development of a new therapeutic strategy for NSCLC.

P14 Activin A is novel circulating biomarker in small cell lung cancer A. Rozsas1,2, M. A. Hoda1, T. Klikovits1, E. Lang3, W. Berger3, W. Klepetko1, B. Hegedus1,4, M. Grusch3, B. Dome1,2,5, V. Laszlo1  ivision of Thoracic Surgery, Department of Surgery, Medical D University of Vienna, Vienna, Austria 2 Department of Tumor Biology, National Koranyi Institute of Pulmonology, Budapest, Hungary 3 Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria 4 Tumor Progression Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary 5 Thoracic Surgery, National Institute of Oncology, Budapest, Hungary 1

Background:  Identification of biomarkers is urgently needed to facilitate the early detection of small cell lung cancer (SCLC) and predicting patients’ responsiveness to different therapeutical strat-

13

egies. Expressions of the growth factor Activin A, and its binding protein, follistatin, are deregulated in a number of malignancies. However, to date there is no data on circulating actvin A and follistatin levels in SCLC. Methods:  Activin A and follistatin plasma levels (PLs) of SCLC patients (n = 79) were analyzed with ELISA. Plasma samples from age- and sex-matched individuals without malignancies served as controls (n = 45). Activin A expressions of primary tumor tissues (n = 42) were analyzed by immunhistochemistry. In vitro Activin A levels of SCLC cell lines (n = 9) were measured with ELISA. Results:  Activin A and follistatin PLs were significantly elevated in patients with SCLC. A significant T-, N- and M-stage-dependent increase in the PLs of activin A, but not of follistatin, was observed. Increased PLs of activin A, but not of follistatin, were associated with significantly shorter overall survival. Furthermore, multivariate analysis revealed that Activin A PL is an independent negative prognostic factor in SCLC patients. Although secretion of activin A was observed in SCLC cell lines in vitro, Activin A protein expressions of the primary tumor tissues did not correlate with the PLs, suggesting that the primary tumor is not the main source of circulating Activin A in SCLC patients. Conclusions:  Our findings suggest that PLs of Activin A and follistatin are elevated in SCLC patients. Moreover, the measurement of circulating activin A can support the diagnosis, staging and prognosis of the disease.

P15 Involvement of the proteases meprins in human lung fibrosis V. Biasin1, M. Wygrecka2, A. Gungl3, B. Ghanim1,4, W. Klepetko4, L. M. Marsh1, A. Olschewski1,5, G. Kwapiszewska1,5  udwig Boltzmann Institute for Lung Vascular Research, Graz, L Austria 2 Department of Biochemistry, Justus-Liebig-University Giessen, Giessen, Germany 3 Medical University of Graz, Graz, Austria 4 Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria 5 Department of Experimental Anaesthesiology, Medical University of Graz, Graz, Austria 1

Background:  Lung fibrosis is a severe disease characterized by collagen deposition and stiffening of the lung. Over-expression of the transcription factor fra-2 in mice (fra-2 tg) leads to development of lung fibrosis, which resembled the human idiopathic pulmonary fibrosis. The protease meprin b is the most upregulated gene in the lung of fra-2 tg mice. Additionally, meprin b and meprin a have been shown to enhance maturation of collagens. Therefore, we speculate that meprins are important players in lung fibrosis. Methods:  Expression level of meprins was tested via qPCR, western blot and immunohistochemistry, while disturbance of the monolayer was assessed by TRITC-dextran permeability assay on A549 cells. Animal model of fibrosis was induced by intra-tracheal administration of bleomycin and lung compliance measured by flexivent. Results:  In this study we observed that meprin a and b were highly expressed in human lung fibrosis and their expression was mostly confined to epithelial cells. In vitro experiments showed that human epithelial A549 cells stimulated with TGF-b increased expression and shedding of meprin b. Functional assay revealed that meprins disturbed the integrity of the epithelial monolayer. In the lung homogenate of bleomycin mouse model, meprin b and meprin a were increased. Confirming the human data, the expres-

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

817

ÖGP

present address: Red Cross Transfusion Service for Upper Austria, Linz, Austria 3 Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria 4 Ludwig Boltzmann Institute for Lung Vascular Research, Medical University of Graz, Graz, Austria 2

ÖGIM

abstracts

ÖGP

ÖGIM

abstracts sion of meprins was elevated in mouse epithelial cells isolated from 14 days bleomycin-treated mice; however meprin a and meprin b KO animals were not protected from bleomycin induced fibrosis as shown by lung compliance measurement and fibrosis analysis. Conclusions:  In conclusion, these data showed a high expression of meprins in fibrotic tissue and epithelial cells of mouse and human samples and their involvement in disturbing the epithelial monolayer integrity. Meprin a and b KO animals were not protected from bleomycin induced fibrosis, however, further studies on double KO animals are needed to better elucidate possible compensatory mechanism.

P16 Increased expression of NPY1R mediates increased vascular reactivity to NPY S. Crnkovic1,2, P. Jain1, B. Egemnazarov1, L. M. Marsh1, B. Ghanim3, W. Klepetko3, P. Holzer4, A. Olschewski1,2, G. Kwapiszewska1,2  udwig Boltzmann Institute for Lung Vascular Research, Graz, L Austria 2 Department of Experimental Anaesthesiology, Medical University of Graz, Graz, Austria 3 Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria 4 Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria 1

Background:  Activation of neurohormonal axis and increased innervation have lately been recognized as important factors in the pathogenesis of pulmonary hypertension (PH). Methods:  Expression of NPY and Y1 receptor were determined by quantitative PCR. Cellular response to NPY stimulation was assessed by Western blotting, thymidine incorporation, calcium imaging and cAMP determination. Vascular reactivity measurements were performed using isolated murine pulmonary arteries from normoxic and chronic hypoxic animals. Selective Y1 receptor antagonist and Y1 knockout mice were used to assess the contribution of receptor subtype in mediating NPY effects. Results:  Pulmonary arteries from IPAH patients have increased number of NPYergic axonal endings and increased expression of NPY Y1 receptor (NPY1R). Increased NPY1R expression was also observed in animal PH models (chronic hypoxia exposed mice, monocrotaline treated rats, Sugen-chronic hypoxia exposed rats). NPY increased intracellular calcium levels, enhanced vasoconstriction of pulmonary arteries preconstricted with adrenaline and stimulated proliferation of human pulmonary arterial smooth muscle cells (hPASMC). Additionally, NPY reduced iloprost-induced cAMP increase in human PASMC (30 ± 15 %, p < 0.05). Y1 receptor antagonist, BIBO 3304, inhibited vasoconstrictive and proliferative effects of NPY (1.13 ± 0.08 vs. 0.95 ± 0.11 relative thymidine incorporation, NPY vs. BIBO 3304, respectively). Finally, pulmonary arteries isolated from mice exposed to chronic hypoxia showed stronger NPYinduced vasoconstriction (1.08 ± 0.44 vs.0.55 ± 0.21  mN, p < 0.05, hypoxia vs. normoxia, respectively). Conclusions:  NPY1R is a necessary and sufficient receptor subtype in mediating NPY’s induction of two key pathogenic hallmarks of PH. Furthermore, results indicate that increased NPY1R expression could mediate increased hypersensitivity to NPY.

P17 Do field safety notes (FSN) published for anesthetic apparatuses and consumables fulfill MEDDEV criteria?—Analysis of FSN published by the BfArM 2005–2013 J. Hannig, R. Siekmeier Drug Regulatory Affairs, Pharmaceutical Institute, University Bonn, Bonn, Germany

Background:  The European Directive 93/42/EEC regulates marketing and post market surveillance of medical devices in the European Economic Area. In cases of incidents and field safety corrective actions (FSCA) manufacturers have to inform responsible Competent Authority (D: BfArM, AU: BASG) and public by field safety notices (FSN). Here FSN for anesthetic apparatuses and consumables were studied in respect to the MEDDEV 2.12–1 rev 8. Methods:  FSCA and FSN published by BfArM 2005–2013 (http://www.bfarm.de/DE/Medizinprodukte/riskinfo/kundeninfo/functions/kundeninfo-node.html) were analyzed. Results:  In 29 published FSCA we found 28/26 German and English FSN (24/22 apparatuses), respectively. FSN were clearly characterized as FSN in 25/20 cases and declaration of type of action was found in 23/24 cases. Product names, detailed information regarding FSCA and reason of the reportable incident were found in 28/26, 28/25 and 28/26 FSN. Lot numbers or other information for product characterization were available in 3/2 and 21/19 cases. Information on product related risks with previous use of affected devices was provided in 26/23 cases and in all cases manufacturers provided information to mitigate product related risks. Comments or descriptions playing down the risk were found in 11/11 cases. Request to pass the FSN to other persons who need to be aware was found in 22/20 cases. In 25/21 cases a contact person or phone number was declared. In apparatuses typical reasons of reportable incidents were manufacturing errors (e.g. failure of electrical components) and software issues resulting in anesthetic risk (delay or stop of therapy) or user risk (e.g. tilting danger). Consumables were mainly affected by production failure resulting in anesthetic risk. Dependent on type and failure of products reported measures for risk mitigation were e. g. additional recommendations for use or reconstruction by the manufacturer. Conclusions:  Most FSN fulfil MEDDEV criteria. However, type and content of FSN should be improved.

P18 Bactericidal activity of N-chlorotaurine against Chlamydia pneumoniae and Chlamydia trachomatis R. Bellmann-Weiler1, V. Maass2, R. Arnitz3,4, G. Weiss1, M. Maass2, M. Nagl4  epartment of Internal Medicine VI, Infectious Diseases, D Immunology, Rheumatology, Pneumology, Medical University of Innsbruck, Innsbruck, Austria 2 Labor Dr. Heidrich & Kollegen, Hamburg, Germany 3 Department of Pulmonary Diseases, Hospital Vöcklabruck, Vöcklabruck, Austria 4 Division of Hygiene and Medical Microbiology, Department of Hygiene, Microbiology and Social Medicine, Medical University of Innsbruck, Innsbruck, Austria 1

818   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

P19 Cartilage oligomeric matrix protein (COMP) as an adaptive mechanisms to the pressure overload in the right ventricle B. Egemnazarov1, S. Crnkovic1, H. Olschewski2, A. Olschewski1,3, L. M. Marsh1, G. Kwapiszewska1,3  udwig Boltzmann Institute for Lung Vascular Research, Graz, L Austria 2 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 3 Experimental Anesthesiology, Department of Anesthesia and Intensive Care Medicine, Medical University of Graz, Austria 1

Background:  Right ventricle (RV) is subjected to pressure overload in many clinical situations like pulmonary embolization and pulmonary arterial hypertension. RV functional status predicts survival of those patients. However, the mechanisms of RV adaptation to pressure overload are poorly understood. The aim of our study was to investigate the function of COMP in the RV pressure overload model. Methods:  RV pressure overload was induced in wild-type (WT) or COMP knockout (KO) mice by pulmonary artery band-

13

ing (PAB). Three weeks post-operation, mice were investigated by echocardiography and invasive hemodynamics. Subsequently, histology and gene expression analysis were performed on RV tissue samples. Results:  PAB generated a significant pressure overload in W T mice (RV systolic pressure (RVSP) in PAB = 48 ± 11 mm Hg vs. sham 29 ± 5  mm Hg, p = 0.001). Echocardiography showed thickened RV free wall, enlarged RV and reduced cardiac. Invasive hemodynamics revealed reduced contractility index, prolonged tau, and elevated EDP. Elevated expression of ANP, BNP and collagens was measured in RV tissue samples. Histologic examination revealed RV fibrosis. Elevated COMP expression was detected in RV tissue, which was localized to vimentin and DDR2 positive cells. PAB operation in COMP KO mice caused RVSP elevation comparable with RVSP in WT mice (COMP KO RVSP = 50 ± 4 mm Hg, p = 0.15 vs. WT PAB). However, COMP KO mice demonstrated worse survival after PAB operation. They demonstrated worsening of diastolic function compared to WT mice as evidenced by prolonged Tau (p = 0.012 vs. WT PAB) and elevated RV EDP (p = 0.005 vs WT PAB). Higher degree of RV fibrosis was revealed by Masson’s Trichrome staining in RV of COMP KO PAB operated mice. Conclusions:  RV in pressure overload model is characterized by systolic and diastolic dysfunction. Absence of COMP led to worse survival, deterioration of RV diastolic function and more pronounced RV fibrosis. Thus, COMP appears as an adaptive mechanism to pressure overload.

P20 The effects of inspiratory muscle training for patients with pulmonary disease in outpatient rehabilitation I. Mittendorfer, P. Kruesmann, C. Puelacher Rehamed Tirol, Center for cardiac and pulmonary outpatient rehabilitation, Innsbruck, Austria

Background:  The effects of inspiratory/respiratory muscle training are widely investigated. Positive effects in healthy humans are established (Hart N. et al. 2011). Beckerman et al. (2005) attested an increase of maximal inspiratory pressure (Pi max), distance of 6  min walking test and Borg Scale data in COPD patients. The main objective of this study was to determine the optimal intensity and frequency of inspiratory muscle training (IMT) in outpatient rehabilitation. Methods:  92 patients were randomized in a training group (with IMT) and control group (no IMT). The patients started with a low load (20–30 % of PiMax) which they increased during the 20 training sessions till they received a maximum of 70 % of Pimax. They startet twice a week with 30 deep breathes supervised by a sport scientist followed by a training at home every other day. After 20 sessions the additional test was done. To figure out the long term compliance, we called the patients once a month after rehabilitation was finished. Results:  There was statistically high significant increase in PiMax from 70.97 cmH2O to 80.32 cmH2O (p < 0.001) and COPD assesment test CAT 15 to CAT 13 (p = 0.001) in experimental but not in control group. Conclusions:  The findings of this study show that the outcome of IMT every other day is positive in different parameters. The goal of the outpatient rehabilitation is to prepare the patients for the home routine training. Additional to endurance, weight and coordination training, IMT is recommended. We will do further investigation to find out the optimal intensity of each training session.

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

819

ÖGP

Chlamydia pneumoniae causes infections of both the lower and upper respiratory tract, such as pneumonia, bronchitis, pharyngitis and sinusitis. In the last few years, it has also been implicated as an infectious trigger for acute exacerbations of asthma and COPD. N-chlorotaurine is a mild endogenous long-lived oxidant, which is thought to exert immune-regulatory and antimicrobial properties during inflammation. It has broad-spectrum bactericidal, fungicidal, virucidal, and protozoocidal activity. NCT proved to be very well tolerated by human tissue and can be used topically at different body sites to treat infections, e.g. in the human eye, on the skin, in the ear and paranasal sinuses, in the oral cavity, and in the urinary tract. NCT caused a concentration- and time-dependent inactivation of C. pneumonia. In chlamydiae treated with 1 % (55  mM) NCT and 0.1 % NCT for 1, 30 or 60  min, or 70 % ethanol for 3  min (positive control), no planar inclusions could be found, indicating loss of chlamydial replication. Lowering the concentration of NCT to 0.01 % resulted in chlamydial growth similar to the controls after 1 and 30 min, while planar inclusions disappeared completely after 60 min incubation time. Prolonged incubation of the inoculated cells for 144  h did not change this result. In experiments with second passage infection after lysis of the host cells hardly any fluorescent IFU could be detected when using lysates from NCT treated cells, whereas in controls an overwhelming infection was seen. Thus, the absence of infectivity of the scarce chlamydial inclusions was confirmed implicating bactericidal activity of NCT against C. pneumoniae. These results were also confirmed by RT-PCR where full chlamydial DNA-replication was found in controls to a high extent, whereas in samples incubated in 0.1 and 1 % NCT relatively low numbers of chlamydial copies were detected. These effects were similar for second passage progeny. NCT at concentrations of 0.1 and 1 % completely inactivated also C. trachomatis serovars A and D after a minimal incubation time of 1 min. 0.01 % NCT for up to 30 min had no effect. N-chlorotaurine is chlamydiacidal and might become a promising candidate to treat chlamydial infections via topical application including inhalation.

ÖGIM

abstracts

abstracts

ÖGP

ÖGIM

P21 Inflammatory profiling of chronic lung disease with associated pulmonary hypertension L. M. Marsh1, E. Stacher1,2, J. Hoffmann1, B. Ghanim1,3, W. Klepetko3, H. Olschewski4, A. Olschewski1,5, G. Kwapiszewska1,5 Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria Department of Pathology, Medical University of Graz, Graz, Austria 3 Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria 4 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 5 Department of Anaesthesiology and Intensive Care Medicine, Experimental Anaesthesiology, Medical University of Graz, Graz, Austria 1 2

Background:  Pulmonary hypertension (PH) is a life-threatening complication in chronic lung disease and is associated with decreased survival. Inflammation is an important component underlying many chronic diseases and has been shown to be associated with the degree of pulmonary vascular remodelling and arterial pressure. In this study we sought to characterise the inflammatory profiles of patients with PH due to chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Methods:  Flow cytometry was used to detect differences in the inflammatory cell populations in lung homogenates (LH) of patients with PH-COPD and PH-IPF. Immunohistochemistry was performed to verify tissue localization. All explant lungs were end stage disease and possessed PH (mPAP ≥ 25 mmHg). Statistical differences were determined by the Kruskal-Wallis with Dunn’s post-hoc test. Results:  In the lungs of PH-COPD patients, elevated numbers of B cells and T cells and T cell subsets were observed. However, these populations were unchanged in PH-IPF lungs compared to donor samples. Similarly, mast cell numbers were increased in PHCOPD but not PH-IPF. Analysis of PH-IPF patients’ lungs revealed increased macrophage/dendritic cell populations. Using immunohistochemistry we could confirm the abundance of macrophage/ dendritic cells in PH-IPF tissue, where they were predominately localised to the fibrotic interstitium and also in the epithelium of honeycombed areas. Conclusions:  Although both groups (PH-COPD and PH-IPF) possessed vascular remodelling and PH, distinct inflammatory profiles were observed. The relevance of these altered cell populations in mediating remodelling remains to be elucidated.

 ivision of Thoracic Surgery, Department of Surgery, Medical D University of Vienna, Vienna, Austria

5

Background:  Pulmonary hypertension (PH) is a progressive and fatal cardiovascular disorder and characterized by a sustained elevation of pulmonary artery pressure. Docosahexaenoic acid (DHA) is an omega-3-fatty-acid, which has been shown to have beneficial effects in the cardiovascular system. But its regulatory effect on vascular tone and pressure in PH is largely unknown. As DHA a potent regulator of potassium (K+) channels, we tested the hypothesis that, DHA can regulate the membrane potential of human pulmonary artery smooth muscle cells (PASMCs) through K+ channels leading to reduction of pulmonary vascular tone and pressure in PH. Methods:  We investigated the acute effects of DHA combining patch-clamping and pharmacology on human PASMCs as well as applying ex vivo and in vivo mouse models including knock-out animals. We have further extended the in vivo studies with using a rat model of PH. Results:  DHA preferentially activated calcium activated potassium (BKCa) channels in human PASMCs. Moreover, DHA significantly hyperpolarized the resting membrane potential of the PASMCs obtained from patients with IPAH compared to healthy donors PASMCs. Using preconstricted mouse pulmonary arteries, DHA led to a dose dependent vasodilation. In our ex-vivo mouse model DHA significantly reduced pulmonary arterial pressure. DHA induced pulmonary vasodilation was significantly damped in the BKCa knock-out mice, indicating the major role of KCa channel in DHA induced vasoregulation in the pulmonary artery. When DHA was applied acutely to two different animal models of PH, DHA led to a profound decreased of the right ventricular systolic pressure. Conclusions:  Our findings indicate that DHA leads to vasorelaxation due to activation of KCa channels in human PASMCs as well as in animal models of PH. Our results provide further molecular insides into the pulmonary vascular effects of DHA pointing out the beneficial effects of DHA as potent vasodilator.

P23 Comparative results of biopsies for patients having a sarcoidosis (salivary gland biopsy for diagnsis of sarcoidosis) M. Bratkovskis Centre of Tuberculosis and Lung Diseases, Riga, Latvia

P22 DHA facilitates rapid pulmonary arterial relaxation via KCa channel mediated hyperpolarization in pulmonary hypertension C. Nagaraj1,2, B. Tang2,3, B. Nagy1,3, R. Papp1, P. Jain1, L. Marsh1, A. Meredith4, W. Klepetko5, B. Ghanim5, A. Olschewski1,2  udwig Boltzmann Institute for Lung Vascular Research, Graz, Austria L Department of Anaesthesiology and Intensive Care Medicine, Experimental Anaesthesiology, Medical University of Graz, Graz, Austria 3 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 4 Department of Physiology, University of Maryland School of Medicine Baltimore, Baltimore, USA 1 2

Background:  An effectiveness of different groups of diagnostic biopsies has been analysed for 856 patients having a sarcoidosis and treated during 2007–2014. in our clinic. The aim of this analysis and research was the determination of diagnostic values. Methods:  1069 distinct biopsies have been carried out and distinguished into folloving groups: (1) The group of salivary glands of mouth cavity. There are 172 positive biopsies (21.6 %) among 797 biopsies. (2) Bronchoscopic biopsies—901. There are 628 positive (69.7 %) among them. (3) Biopsies due to operations. There are 47 positive biopsies among 47 (100 %) biopsies (VATS—1.6 % of all biopsies). Conclusions:  Results of biopsies for patients having a sarcoidosis in Latvia vary from 21.6 to 100 % (VATS). Folloving to our experience the biopsy of salivary glands of mouth cavity is effective: This biopsy is technically easy performed by a dentist. There are no complication during this research. This easy and mostly ambulant biopsy has the effectiveness (21.6 %).

820   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

Endobronchial valve treatment in patients with COPD and heterogeneous emphysema without collateral ventilation M. A. Grasl1, G. Ambrosch2, M. Duller1, C. Abele, M. C. Leitgeb1, S. Asadi1, O. C. Burghuber1, A. Valipour1 Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Otto-Wagner-Spital, Vienna, Austria 2 Department of Pneumology, LKH Graz Süd-West, Graz, Austria 1

Background:  There is increasing evidence for bronchoscopic endobronchial valve (EBV) therapy in patients with severe emphysema. The aim of the current study was to analyse lung function changes of this novel technique in routine clinical practice since the introduction of real-time assessment of collateral ventilation. Methods:  Multicentre, retrospective, case-series of patients with severe symptomatic emphysema despite optimal medical management and at least one follow-up visit after treatment. Patients included were required to have heterogeneous emphysema based on visual computed lung tomography assessment and hyperinflation on bodyplethysmography. Collateral ventilation was excluded using Chartis measurements. Patients with unstable comorbidities, severe bronchiectasis, hypercapnia (paCO2 > 55 mmHG), and pulmonary arterial hypertension (sPAP > 50 mmHG) were excluded. Results:  Sixty-four patients with a mean ± SD age of 66 ± 7 yrs, FEV1 27 ± 7 % predicted, and a residual volume of 308 ± 72 % were included in this cohort. There were statistically significant improvements in FEV1, total lung capacity, and residual volume within a 6 month follow-up period (p < 0.05 for all). Reductions in lung volumes persisted in the subgroup of patients with available follow-up data of at least 2 years. 15 subjects (23 % of treated population) had a postprocedural pneumothorax. Conclusions:  Endobronchial EBV therapy in patients with severe, heterogeneous emphysema and complete interlobar fissures is associated with favourable clinical outcomes outside of clinical trials. Table 1  Lung function prior to and after EBV therapy Baseline

6 months

p-values

FEV 1 (L)

0.76 ± 0.25

0.88 ± 0.29

0.014

FEV1 %

27 ± 7

32 ± 10

0.004

TLC (L)

7.8 ± 1.5

7.3 ± 1.5

0.048

TLC %

147 ± 20.2

139 ± 20.5

0.017

RV (L)

5.5 ± 1.2

4.8 ± 1.4

0.007

RV %

308 ± 72

252 ± 69

< 0.001

The Austrian Severe Asthma Registry D. Doberer1, W. Auer2, J. Löffler-Ragg3, C. Kähler3, K. Moritz1, M. Kneussl1, J. Messner4, F. Lins5, P. Cerkl5, E. Kaufmann6, M. Flicker6, S. Klade7, B. Lamprecht7, M. Rowhani8, R. Mikes9, M. Studnicka9, A. Zacharasiewicz10, K. Marth11, W. Pohl11, B. Lang12, J. Eckmayr12, F. Wantke13  epartment of Internal Medicine II (Pneumology), Wilhelminenspital, D Vienna, Austria Department of Internal Medicine, Krankenhaus der Elisabethinen, Graz, Austria 3 Department of Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria 4 Pulmonary Specialist, Salzburg, Austria 5 Department of Pneumology, LKH Hohenems, Hohenems, Austria 6 Department of Pneumology, LKH Leoben, Leoben, Austria 7 Department of Pneumology, AKH Linz, Linz, Austria 8 Pulmonary Specialist, Vienna, Austria 9 Department of Pneumology, Paracelsus Private Medical University, Salzburg, Austria 10 Department of Pediatrics and Adolescent Medicine, Wilhelminenspital, Vienna, Austria 11 Department of Pneumology, KH Hietzing, Vienna, Austria 12 Department of Pneumology, Klinikum Wels-Grieskirchen, WelsGrieskirchen, Austria 13 Floridsdorfer Allergiezentrum, Vienna, Austria 2

The Austrian Tobacco Law 2015: hope for a smokefree Austria? M. Neuberger1,2 Institute of Environmental Health, Medical University of Vienna, Vienna, Austria 2 Austrian Academy of Science, Commission Climate & Air Quality, Vienna, Austria

13

P26

1

P25

1

Background:  An amendment of the tobacco law was voted on July 8th, 2015 in the Austrian parliament. Methods:  The government proposal is analyzed by comparison with other EU legislation. Results:  Progress was made by elimination of smoking rooms from the hospitality industry. All guest rooms including tents and multipurpose rooms are made smoke-free, also kitchens. Smoking rooms are still allowed in hotels, but without service or use for preparation or consumption of food or drinks. Clubs have to be smokefree if used for events or granting access to children and adolescents. Paid transport of persons has to be smoke-free, but tobacco shops only if used for mail parcel service. After May 20, 2016 use of water-pipes, e-cigarettes and similar products will be banned, where smoking is prohibited. An unnecessary burden to tax-payers was the 30 % remuneration of innkeepers for earlier investment costs to separate smoking rooms. Smoking rooms in hotels still need regulation of ventilation, child access and use for other purposes (gambling, TV, internet, etc.). The most severe shortcoming of the new law is lack of enforcement of its introduction by police control. Missing are advertising bans for all cigarettes. Vending machines are not child-proof and should be removed. A display ban would be necessary for tobacco shops accessible to underaged (for buying magazines, sweets, softdrinks, etc.). The government also failed to raise the legal age for buying cigarettes from 16 to 18 years and to ban smoking in hospitals and health-care facilities. The long overdue ban of smoking in restaurants and bars does not enter into force before May 2018, which is irresponsible. Conclusions:  The draft tobacco legislation is a placebo for the hospitality industry and gives right wing parties another three years of time to stoke fears and manipulate public opinion with financial support of the international tobacco industry.

Patients with severe asthma (SA) represent a small group of the asthmatic population but with the highest burden of disease and unmet medical needs. In 2012 the Austrian Severe Asthma Network (ASANet) was founded and a National Severe Asthma Registry launched

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

821

ÖGP

P24

ÖGIM

abstracts

ÖGP

ÖGIM

abstracts

to improve the understanding of epidemiology, underlying mechanisms and disease progression of SA in Austria. As of July 10, 2015 16 participating centers from both the hospital and registered doctors’ sector joined the network and recruited 71 adult SA patients (mean age ± SD 55.6 ± 15.1 yr, 53 % males, BMI 26.2 ± 5.1  kg): 91 % were diagnosed with asthma after age 12, 46 % allergic asthma, 84 % uncontrolled or partly controlled asthma (GINA), with 4.3 ± 4.7 exacerbations during the last 12 months, high rate of comorbidities (70 % cardiovascular disease, 50 % chronic sinusitis, 48 % recurrent lower respiratory tract infections, 27 % GERD, 26 % depression, 21 % COPD, 18 % aspirin exacerbated respiratory disease) and 63 % with corticosteroid-induced side effects; mean FEV1 was 1.71 ± 0.77 L (55 ± 21 %), total serum IgE 423 ± 493  U/mL, exhaled NO 44 ± 28  ppb and 54 % with blood eosinophilia (≥ 300 /mL); 94 % were on ICS/LABA treatment, 58 % on LAMA, 52 % on oral corticosteroids (mean prednisolone equivalent dose 11.2 ± 7.8 mg), 48 % received omalizumab. Recruitment of additional patients and centers is ongoing and yearly follow-ups will enable longitudinal assessment in the future.

P27 Pulmonary arterial tortuosity as a non-invasive diagnostic tool for pulmonary arterial hypertension M. Pienn1, C. Payer1,2, G. Kovacs1,3, V. Foris1,3, M. Urschler2,4, A. Olschewski1,5, H. Olschewski1,3, Z. Bálint1  udwig Boltzmann Institute for Lung Vascular Research, Graz, L Austria 2 Institute for Computer Graphics & Vision, University of Technology, Graz, Austria 3 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 4 Ludwig Boltzmann Institute for Clinical-Forensic Imaging, Graz, Austria 5 Department of Experimental Anaesthesiology, Medical University of Graz, Graz, Austria 1

Background:  Pulmonary hypertension (PH) is a chronic disorder of the pulmonary circulation, marked by an elevated vascular resistance and pressure. We hypothesized that, patients with increased pressure in the pulmonary arteries will have increased arterial tortuosity. Methods:  We present an automatic pulmonary vessel tree extraction algorithm, which uses contrast-enhanced thoracic CT images as input and identifies individual arterial or venous vessel trees. A vessel enhancement filter was used to find vertices along the vessel centrelines in the lung, which were connected to vessel trees using an integer program. Finally, the automatic vessel labeling is performed based on anatomical measures. We used datasets of patients, without comorbidities, who underwent right heart catheterization and thoracic CT examination. The tortuosity was calculated for each vessel segment and its mean value was compared to the patient’s diagnosis and clinical data. Results:  Nineteen patients (5 without, 14 with PH) were analyzed retrospectively. There was no difference in the detected number of vessel segments between the two groups. Comparing patients with and without PH, in the arteries we found a slightly higher difference in the mean tortuosity (PH: 1.037 vs. noPH: 1.028, p = 0.018) than in all the vessels (PH: 1.036 vs. noPH: 1.029, p = 0.008) or in the veins (PH: 1.034 vs. noPH: 1.029, p = 0.008). The tortuosity of the arteries positively correlated with mean pulmonary arterial pressure (rart = 0.74). This was similar to the correlation when all the vessels were considered (rall = 0.75), whereas the veins showed a modest correlation of rveins = 0.58. ROC analysis showed a good power for the arterial tortuosity to discriminate patients with and without PH (Area under the curve: 0.87).

Conclusions:  Our fully automatic algorithm provides quantitative readouts of the individual vessel types from thoracic CT images. The power of the arterial tortuosity measure to identify the presence of PH provides a possible tool to non-invasively diagnose pulmonary hypertension.

P28 Clinical value of component-based diagnosis in pollen-allergic patients F. Horak, M. Darwisch, E. Derntl, U. Enzenberg, I. Hahn, S. List, B. Novak, L. Soti, M. Sotoudeh, U. Thurner, B. Tichatschek, B Vukicevic, C. Wagner, E. Zounek Allergy Center Vienna West, Vienna, Austria

Background:  Component-resolved analysis has gained importance especially in the diagnosis of food-allergies. However it is not clear if specific components can also improve diagnosis of pollenallergies or help in the decision to start specific immunotherapy (SIT). Methods:  We retrospectively evaluated patients that were referred to the Allergy Center Vienna West for suspected grass, birch, ragweed, and/or mugwort allergy and were tested for extracts as well as the respective components (Phl p 1, 5, 7; Bet v1, 2, 4; Art v1, 3 and Amb a1) measured by ImmunoCAP. Pearson-CorrelationCoefficients (CC) were calculated between extracts and main components and patients were analyzed on an individual level to see whether component analysis gave additional information for clinical decisions. Results:  We found a high correlation between birch-extract and Bet v1 (CC = 0.89, p < 0.0001) as well as between grass extract and Phl p1,5 (CC = 0.91, p < 0.0001). Positive extract-results and negative component-results (Bet v1 and Phl p1,5) were only relevant for 1 respective patient, where SIT was not recommended. Concerning mugwort- and ragweed allergic patients we found high rates of double-sensitization (41.2 %) against both weeds. Analyzing this group using component analyses we could see, that only 1/3rd of these patients had a real double-allergy against mugwort and ragweed (Amb a1 pos./Art v1 pos.), while about 1/2 was only ragweed allergic (Amb a1pos./Art v1 neg.) and 1/5th only mugwort allergic (Amb a1 neg./Art v1 pos.). This was relevant for the decision of SIT in 15 % of suspected mugwort-allergic and 10 % of suspected ragweed-allergic patients. Conclusions:  In a clinical setting, component resolved diagnosis was important for a significant number of patients with suspected mugwort- and/or ragweed-allergy. In patients suspected for grass or birch-allergy, components did not seem to give additional information in our patients’ group.

P29 The zebra in the emergency department: a rare cause of acute dyspnoea and chest pain D. Voganjac1, M. Eibl2, S. Oswald3, C. Schnedl3, K. Amrein1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria 2 Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 3 Department of Radiology, Medical University of Graz, Graz, Austria 1

822   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

Results:  One-, 5- and 10-year cancer specific survival (CSS) was as follows: 97.8, 93.8 and 89.3 %. CSS was significantly worse in TETs with Masaoka-Koga stage III–IV compared to I–II (p = 0.005), incompletely resected TETs (p > 0.001) and WHO type B2, B3 thymomas and TCs (p = 0.022). Patients presented with Masaoka-Koga stage I (20.4 %), II (38.3 %), III (14.8 %), and IV (24.1 %). In approximately 85.8 % of cases, a complete resection (R0) could be reached. Multimodality treatment was performed in 52.5 % of patients. We have treated 30 patients with recurrences (incl. 15 referrals). There were 7 local, 9 regional and 14 distant recurrences. One-, 5- and 10year freedom from recurrence (FFR) was as follows: 93.1, 77.4 and 66.2 %. FFR was significantly worse for Masaoka-Koga stage III and IV (p < 0.001) and B2, B3 thymomas and TCs (p = 0.018). Conclusions:  Completeness of resection, WHO histology and Masaoka–Koga tumor stage were significant prognostic factors. Multidisciplinary treatment of patients with thymoma or thymic carcinoma results in excellent patient care.

P31 Women in academic medicine E. Schadelbauer, K. Amrein Medical University of Graz, Graz, Austria

Conclusions:  We report a highly unlikely cause for a common complaint in the ED where CT and biopsy of the breast allowed for safe and rapid diagnosis, avoiding the high periinterventional risk for diagnostic mediastinoscopy in the presence of mediastinal mass syndrome, pleural and pericardial effusions.

P30 Prognostic factors for thymomas and thymic carcinomas: Masaoka-Koga stage, WHO classification and completeness of surgical resection

Background:  Even though the number of women in academic and clinical medicine is continually rising and women now are the majority in many disciplines of medicine, they less often than men reach powerful academic positions such as being an editorial board member. Methods:  We counted men and women on the editorial boards of the top 10 ranked medical journals of the Respiratory System category of the 2014 Thomson Reuters Journal Citation Report. The required information was collected from the journals’ website. One journal (Chest) did not give full information on the editorial board on its website. Results:  The percentage of women editors varied between 9 % (Journal of Thoracic and Cardiovascular Surgery) and 29 % (Journal of Thoracic Oncology). The average percentage of women editors in this category was 17.8 %. Individual results are given in the Figure In comparison, the percentage of women as members in societies in the field of respiratory diseases is substantially higher (e.g. Austrian Society of Pneumology/ÖGP: 45 %).

B. Moser, S. Janik, J. R. Matilla, G. Lang, C. Aigner, J. Ankersmit, S. Taghavi, W. Klepetko Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria

Background:  Thymomas and thymic carcinomas are rare malignant tumors initially diagnosed by pulmonologists and radiologists. We report on the experiences of the resection and multidisciplinary treatment at Department of Thoracic Surgery, Medical University Vienna from January 2001 to May 2015. Methods:  We performed a retrospective analysis of our prospective database. During the last 15 years 194 resections on 151 patients for thymomas and thymic carcinomas (TCs) or their recurrences were performed. We sought to determine prognostic factors in this patient population.

13

Conclusions  Less than one in five editors of major journals in the field of respiratory diseases is a woman. The reasons and possibilities how to improve this are beyond this study, but certainly merit further research.

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

823

ÖGP

Background:  Chest pain and dyspnoea are common symptoms in the emergency department (ED) (1). Even when symptoms and history point to a likely diagnosis (“if you hear hoof beats, think horses”), clinicians should stay open-minded (occasionally it is a zebra). Methods:  Clinical case report. Results:  A 23-year-old woman presented to the ED with chest pain and dyspnoea after driving 16  h. She used hormonal contraception and smoked. Vital signs and laboratory exams were normal except for tachycardia (105 beats/min), elevated D Dimer (1.40  mg/l), mild anemia (Hb 10.5  g/dl) with an otherwise unremarkable differentiated blood count. The Wells Score gave an intermediate probability for pulmonary embolism, which was excluded by computed tomography (CT). Surprisingly, extensive bilateral pleural effusions (Figure, black arrows), a mediastinal mass of 6 cm (white arrows) and pericardial effusion were present. Detailed clinical examination revealed a 2 cm lump in the left breast, which gave a diagnosis of a T-lymphoblastic lymphoma. After appropriate therapy, the patient today remains in complete remission.

ÖGIM

abstracts

abstracts

ÖGIM

P32 Survival and cardiopulmonary comorbidities in patients with high-normal- and borderline-PAP elevation

ÖGP

P. Douschan1,2, G. Kovacs1,2, V. Foris1,2, A. Avian3, A. Olschewski1, H. Olschewski1,2  udwig Boltzmann Institute for Lung Vascular Research, Graz, L Austria 2 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 3 Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria 1

Background:  In patients with pulmonary hypertension (PH) cardiopulmonary comorbidities may contribute to elevation in pulmonary arterial pressure (PAP). The distribution of comorbidities according to PAP, their impact on survival and the prognostic relevance of high-normal-PAP have not yet been systematically addressed. Methods:  Cardiopulmonary comorbidities and hemodynamics of patients with suspected PH undergoing right heart catheterization in our center were retrospectively analysed. Patients were stratified into 6 groups according to mPAP (≤ 17  mmHg: low-normal; 18–20 mmHg: high-normal; 21–24 mmHg: borderline; ≥ 25 mmHg: tertials for mild, moderate and severe PH and PAH). Kruskal-Wallis- and post-hoc-U-Tests were performed to check for differences between mPAP-groups regarding frequency of comorbidities. Kaplan-Meier- and multivariate COX-Regression analysis for survival were performed. Results:  547 patients were analysed (64 % female, age: 62 ± 14 yr, mean PAP: 29.6 ± 15.1  mmHg). A significant difference regarding number of comorbidities across PAP-groups was found in PH (p < 0.001) and PAH (p < 0.001). Patients with high-normal-, borderline-PAP and PH had more comorbidties than patients with lownormal-PAP values (p < 0.001). Patients with mild and moderate PH or PAH had more comorbidities as patients with severe PAP-elevation (p < 0.001–p = 0.007). Number of comorbidities was a significant predictor for survival (p < 0.001) with worst survival in patients with three or more comorbidities (p < 0.001). Patients with high-normaland borderline-PAP and with PH and PAH had worse survival than patients with low-normal-PAP (p < 0.001–p = 0.026). Multivariate Cox Regression analysis for PH patients revealed that both number of comorbidities (p = 0.046; 1 comorbidity: HR 1.3 95%CI 0.8–2.1; 2 comorbidities: HR 1.7 95%CI 1.0–2.8; ≤ 3 comorbidities: HR 2.1 95%CI 1.2–3.7) and mPAP (p ≤ 0.001; 18–20  mmHg: HR 2.3 95%CI 1.0–5.4; 21–24 mmHg: HR 3.1 95%CI 1.4–6.8; 25–35 mmHg: HR 3.9 95%CI 1.9–7.9; 36–48  mmHg: HR 5.0 95%CI 2.5–10.1; ≥ 49  mmHg: HR 6.0 95%CI 3.0–11.7) are independent predictors of survival. Conclusions:  In patients at risk for PH high-normal- and borderline-PAP is associated with higher number of comorbidities and worse prognosis as compared to patients with low-normal-PAP.

P33 Current situation of malignant pleural mesothelioma in Austria: data from the Austrian Mesothelioma Interest Group (AMIG) database Y. Dong1, T. Klikovits1, P. Stockhammer1, M. Arns2, P. Schenk2, W. Pohl3, K. Kirchbacher4, M. Kneussl4, C. Geltner5, W. Wandschneider6, H. Baumer6, M. Studnicka7, P. Porsch7, P. Cerkl8, T. Hernler8, S. Zöchbauer9, M. Flicker10, J. Eckmayr11, C. Trockenbacher11, G. Blazek3, H. Jamnig12, G. Ambrosch13, F. Augustin14, P. Errhalt15, S. Handzhiev15, M. Speiser15, H. Olschewski16, J. Polachova16, R. Wurm16, E. Bitterlich17, B. Baumgartner17, N. Hasenhüttl18, H. Popper19, J. Bolitschek20, S. Wonisch21, B. Machan21, M. A. Hoda1, W. Klepetko1, on behalf of the AMIG study group22  ivision of Thoracic Surgery, Department of Surgery, Medical D University of Vienna, Vienna, Austria 2 Department of Pulmonology, Landeskrankenhaus Hochegg, Hochegg, Austria 3 Department of Pulmonology, Krankenhaus Hietzing, Vienna, Austria 4 Department of Pulmonology, Wilhelminenspital, Vienna, Austria 5 Department of Pulmonology, Landeskrankenhaus Klagenfurt, Klagenfurt, Austria 6 Department of Cardio-Thoracic Surgery, Landeskrankenhaus Klagenfurt, Klagenfurt, Austria 7 Department of Pulmonology, University Clinic Salzburg, Salzburg, Austria 8 Department of Pulmonology, Landeskrankenhaus Hohenems, Hohenems, Austria 9 Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria 10 Department of Pulmonology, Landeskrankenhaus Leoben, Leoben, Austria 11 Department of Pulmonology, Landeskrankenhaus Wels, Wels, Austria 12 Department of Pulmonology, Landeskrankenhaus Natters, Natters, Austria 13 Department of Pulmonology, Landeskrankenhaus Graz West, Graz, Austria 14 Department of Surgery, University Clinic Innsbruck, Innsbruck, Austria 15 Department of Pulmonology, Landeskrankenhaus Krems, Krems, Austria 16 Division of Pulmonology, Department of Internal Medicine, Universitiy Clinic Graz, Graz, Austria 17 Department of Pulmonology, Landeskrankenhaus Vöcklabruck, Vöcklabruck, Austria 18 Department of Pulmonology, Landeskrankenhaus HörgasEnzenbach, Enzenbach, Austria 19 Department of Pathology, Universitiy Clinic Graz, Graz, Austria 20 Department of Pulmonology, Hospital of Elisabethinen Linz, Linz, Austria 21 AUVA Rehabilitation Clinic Tobelbad, Tobelbad, Austria 22 AMIG Office at the Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria 1

Background:  Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from the pleural cavity with strong association to previous asbestos exposure. Despite tremendous efforts in early diagnostics and therapeutic approaches, outcome for MPM patients remains dismal. In order to determine demographics, diagnostics, therapeutic strategies and prognosis of MPM patients in Austria, the Austrian Mesothelioma Interest Group (AMIG) was initiated in 2011. We intend to report on the current data from the AMIG MPM database. Methods:  A prospective cohort study starting from January 2011 was conducted. Follow up was completed until July 2015.

824   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

abstracts

P34 Extrapleural pneumonectomy with or without a trimodality treatment regime for malignant pleural mesothelioma: a retrospective cohort study in a high volume center T. Klikovits, M. A. Hoda, P. Stockhammer, Y. Dong, J. Matilla, S. Taghavi, G. Lang, W. Klepetko, C. Aigner Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria

Background:  Malignant pleural mesothelioma (MPM) is an aggressive thoracic tumor with dismal outcome. Macroscopic complete resection within a multimodality protocol is indicated in patients being fit for surgery. Aim of this study was to investigate short- and long-term outcome of MPM patients undergoing extrapleural pneumonectomy (EPP) within a trimodality treatment (TMT) protocol (induction chemotherapy (CHT), EPP and postoperative intensity modulated radiotherapy (IMRT)) or within other treatment regimens. Methods:  A retrospective review of a prospective database of 101 patients undergoing EPP within different treatment modalities between 1994 and 2015 at our institutions was conducted. Results:  73 males and 28 females with a mean age of 64 ± 11.9 years at the time of diagnosis were included. 38 patients underwent EPP within TMT, 43 patients within other multimodality regimens and 20 patients EPP alone. Main histological subtype was epitheloid (n = 77; 76 %). Postoperative complication rate was 41 %. 30-day mortality was 5.9 % (n = 6) and 90-day mortality was 14.9 % (n = 15). Mean progression free survival (PFS) was 17.8 months (95 % confidence interval (CI) 10.6–25). Overall 3- and 5-year survival rates were 36 % and 31 %, respectively. 5-year survival was significantly better in patients with EPP within TMT (60 %) compared to patients with EPP within other multimodality regimens (23 %; p = 0.047) and EPP alone (13 %, p = 0.01). In the multivariate survival analysis, type of treatment modality (EPP within TMT vs. rest, p = 0.011) and age (≥ 65 years, p = 0.028) were found to be independent prognostic factors for survival.

13

ÖGIM

Conclusions:  EPP within a trimodality protocol is a feasible treatment option with good short and long term outcome. EPP alone offers dismal survival and should be avoided.

P35 5-year-results of a prospective, single-center Lung Metastasis Registry

ÖGP

Results:  203 patients with histologically confirmed MPM were included. There were 162 male and 41 female patients with a mean age of 67.1 (SD ± 11.4) years at the time of diagnosis. Asbestos exposure was confirmed in 103 (50.1 %) patients. 158 (77.8 %) patients were diagnosed with pleural biopsy, 18 (8.9 %) with pleural puncture and 27 (13.3 %) with other approaches. 190 (93.6 %) patients had a chest computed tomography (CT), 120 (59.1 %) received additional positron emission tomography (PET)/CT and 20 (9.9 %) a PET. Histological subtype revealed epithelioid in 133 (65.5 %), sarcomatoid in 15 (7.4 %), biphasic in 28 (13.8 %), desmoplastic in 4 (2.0 %) and not otherwise specified in 23 (11.3 %) patients. 34 (16.7 %) patients received best supportive care only, 59 (29.1 %) chemotherapy (CHT) alone, 3 (1.5 %) radiotherapy (RT) alone, 19 (9.4 %) CHT/RT, 1 (0.5 %) surgery alone and 72 (35.5 %) curative surgery within multimodality treatment. Median overall survival was 17.9 (95 % CI, 14.6–21.3) months. 1-, 3- and 5-year overall survival was 66 %, 26 % and 19 % and was significantly better in patients undergoing surgery within multimodality treatment (5-year survival 14 % vs 35 %, p = 0.001). Conclusions:  Diagnostic and therapeutic approaches according to international guidelines are homogenous among different centers in Austria. Patients undergoing multimodality treatment including surgery had a favorable outcome.

K. Hoetzenecker1, O. Glueck1,2, C. Glogner1,2, C. Nikolowsky2, T. Schweiger1,2, C. Aigner1, W. Klepetko1  ivision of Thoracic Surgery, Department of Surgery, Medical D University of Vienna, Vienna, Austria 2 Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration, Medical University of Vienna, Vienna, Austria 1

Backgound:  Pulmonary metastasectomy with curative intent is nowadays an essential part in the interdisciplinary treatment of patients with pulmonary spreading. However, most of the available literature is based on retrospective analyses. In order to improve data quality in the field of pulmonary metastasectomy, we established a computer-based, prospective database in our department. All included patients were followed-up by a dedicated team. Methods:  All patients receiving pulmonary metastasectomy with curative intent between 2009–2014 were included in the database and regularly followed-up. More than 300 parameters were recorded for every patient. Complete data sets are available for more than 95 % of patients. Results:  To date 271 patients were included in the database. In this patient cohort, colorectal cancer patients account for the majority of cases (25 %), followed by osteosarcoma (10 %) and renal cell cancer patients (10 %). Mean disease-free survival (time from diagnosis of the primary to pulmonary spreading) was 54.3 months. Most of our patients recieved parenchyma sparing resections: 40 % wedge resections, 31 % laser enucleations, and 20 % electrocautery enucleations. In only 9 % of patients metastases were resected by an anatomical resection. A mean of 1.8 nodules (range 1–60) were resected per patient. In 40 % of all cases, a re-metastasectomy had to be performed during the follow-up. 3-year survival was 73.8 % for colorectal cancer patients, 57.6 % for renal cell cancer patients, 50.7 % for sarcoma patients, 80 % for breast cancer patients and 23.2 % for melanoma patients. Conclusions:  Based on our database, we were able to publish several original articles in peer-reviewed journals. A well-defined, prospective patient cohort is a prerequisite in order to perform studies in the field of pulmonary metastasectomy.

P36 Single-stage laryngotracheal reconstruction in adults without prolonged postoperative stenting K. Hoetzenecker1, T. Schweiger1, S. Schwarz1, I. Roesner2, M. Leonhard2, D. Denk-Linnert2, B. Schneider-Stickler2, W. Bigenzahn2, W. Klepetko1  ivision of Thoracic Surgery, Department of Surgery, Medical D University of Vienna, Vienna, Austria 2 Division of Phoniatrics-Logopedics, Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria 1

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

825

ÖGP

ÖGIM

abstracts Background:  The standard technique for subglottic stenosis is a classical cricotracheal resection, first introduced by Grillo and colleagues. Although it is considered a challenging procedure, it is associated with excellent long-term results. However, a high number of failures is reported in the literature when the stenosis is characterized by an advanced side-to-side narrowing and reaches the level of the vocal cords. For these kind of stenoses laryngotracheal reconstructions (LTR) using cartilage interpositions have to be performed. This technique usually requires a prolonged postoperative stabilization of the reconstructed airway with a stent. Herein, we report our first experience of a modified LTR without the need of a prolonged postoperative stenting. Methods and results:  From 2012–2015 five consecutive cases of laryngotracheal stenosis were surgically corrected by the Laryngotracheal Team Vienna. All patients suffered from a combination of pronounced submucosal thickening and an advanced side-to-side narrowing extending to the level of the vocal fold. Thus, a sufficient lumen enlargement could not be achieved by a standard CTR. In all cases the cricoid plate was completely split in the midline and a rib cartilage was introduced in order to enlarge the subglottic diameter. In contrast to the originally described technique of Couraud et al., the lateral edges of the cartilage graft were trimmed in a stepwise fashion. This led to a completely stable positioning of the graft within the split cricoid. Since the laryngotracheal reconstruction was firm without any instability or collapse, no stent was needed for postoperative stabilization. The perioperative course was uneventful and all patients and the functional outcome was excellent with a normal ventilation, swallowing and voice function 3 months after the operation. Conclusions:  We therefore conclude that by our proposed modifications, LTR can be performed safely without the need of postoperative stenting of the reconstructed airway.

P37 Current practice in prehospital management of acute exacerbations of chronic obstructive pulmonary disease in Austria: retrospective data analysis P. Zajic, G. Prause Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria

Background:  Acute exacerbations of COPD (AECOPD) are common presentations for emergency medical services (EMS) in developed countries. Optimum management of these patients is based upon sound evidence that has been translated into clinical practice guidelines (e.g. GOLD guideline). However, common practice in Austria’s physician based EMS is unknown. Methods:  All reports on calls due to AECOPD for the emergency physician system based at the University Medical Center of Graz between January 2010 and June 2015 were queried. Descriptive statistical methods were performed to represent current management practice. Results:  163 individual cases were identified. 4 cases were excluded since AECOPD was deemed the cause for cardiac arrest, which was managed according to current resuscitation guidelines. Frequencies of performed interventions are presented in Table 1. Conclusions:  AECOPD is primarily managed by bronchodilative medication in the prehospital setting. Bronchodilators are applied inhalative or intravenous at similar rates. Corticosteroids are almost exclusively given intravenously at relatively high doses (68 % > 100  mg prednisolone). NIV is used frequently and usually requires sedation. Invasive mechanical ventilation is necessary only rarely. High rates of accompanying circulatory disturbances (i.e. hypertension, tachycardia) requiring treatment were observed.

Table 1 Intervention

n

%

Beta agonists/anticholinergics (intravenous, subcutaneous)

40

25.2

Beta agonists/anticholinergics (inhalative)

34

21.4

Beta agonists/anticholinergics (both routes)

 9

5.7

Theophylline

17

10.7

Inhalative

 1

0.1

Intravenous

76

47.8

Invasive (CMV)

 7

4.4

Non-invasive (NIV)

45

28.3

Diuretics

25

15.7

Antihypertensives

33

20.8

Antiarrhythmics

10

6.3

Cathecholamines

 1

0.1

Sedation

45

28.3

Bronchodilators

Corticosteroids

Ventilation

Circulatory

P38 Prognosticators in a large cohort of malignant pleural mesothelioma patients treated in eastern Austria: a retrospective study over 20 years P. Stockhammer1, Y. Dong1, T. Klikovits1, M. Arns2, P. Schenk2, W. Pohl3, M. Flicker4, P. Errhalt5, W. Klepetko1, M. A. Hoda1  ivision of Thoracic Surgery, Department of Surgery, Medical D University of Vienna, Vienna, Austria 2 Department of Pulmonology, Landeskrankenhaus Hochegg, Hochegg, Austria 3 Department of Pulmonology, Krankenhaus Hietzing, Vienna, Austria 4 Department of Pulmonology, Landeskrankenhaus Leoben, Leoben, Austria 5 Department of Pulmonology, Landeskrankenhaus Krems, Krems, Austria 1

Background:  Malignant pleural mesothelioma (MPM) is a devastating malignancy strongly related to prior asbestos exposure. Due to the rising incidence and dismal prognosis, improved diagnostic and therapeutic management is urgently needed. The aim of our study was to identify prognostic parameters in a large cohort of MPM patients. Methods:  All patients with histologically confirmed MPM, treated at specialized centers in eastern Austria between 1994 and 2014 were included. We investigated the effect of different clinical and pathological characteristics and laboratory values on patient outcome. Results:  Of 252 patients (188 male and 64 female), mean age at diagnosis was 64 years (range 27–91 years). Main histological subtype was epitheloid (n = 162, 64 %). Multimodality treatment, defined as macroscopic complete resection combined with chemotherapy and/ or radiation therapy, was performed in 133 (43 %) patients. Median survival in the whole cohort was 16.13 months from diagnosis, 1-year survival rate was 51.0 %, 2-year survival rate was 24.7 %. When using univariate as well as multivariate analyses, following variables were associated with a poor prognosis: elevated Glasgow Prognostic Score (GPS) at diagnosis (p < 0.001) and before surgery (p < 0.003), low

826   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

P39 Preoperative serum C-reactive protein predicts longterm outcome in patients undergoing resection for early stage NSCLC B. A. Marzluf, T. Krajc, M. R. Müller Department for Thoracic Surgery, Otto Wagner Hospital, Vienna, Austria

Background:  Inflammation has been shown to contribute to tumor pathogenesis and progression. We hypothesized that elevated preoperative serum C-reactive protein (CRP) is a predictor of worse outcome in patients who underwent anatomical lung resection for NSCLC in stage I. Methods:  We conducted a single center retrospective cohort study including patients operated on for NSCLC in stage I between 2002 and 2009. Data recorded apart from preoperative CRP included sex, age, tumor histology, type of surgical procedure, preoperative lung function parameters, preoperative radiation and chemotherapy, surgical and non-surgical complications, and comorbidities. Data on mortality and cause of death up to 2012 were obtained from Statistics Austria. We assessed the influence of CRP on survival by Kaplan Meier and multivariate Cox regression analysis. The study has been approved by the local ethics committee. Results:  A total of 684 patients (mean age 62.4 ± 9.4 years; 62.4 % males) were included. The majority of patients had adenocarcinoma (56.0 %) and underwent lobectomy (88.7 %). Overall mean preoperative CRP was 14.2 ± 29.9 mg/l. For CRP = 12.5 mg/l as cutoff value, survival was significantly better for lower (median 3699 days, n = 516) than for higher (median 2022 days, n = 168) CRP by Kaplan Meier analysis and log rank test (p < 0.00001). Multivariate Cox regression analysis identified preoperative CRP as an independent predictor of outcome (HR = 1.004 per increase of 1 mg/l, 95 % CI 1.001–1.008; p = 0.013), in addition to sex, age, and non-surgical complications. Conclusions:  Elevated levels of preoperative CRP indicate worse long-term outcome in patients after radical resection for stage I NSCLC stage.

P40 Why NOT: think CF! Three cases of late diagnosis despite newborn screening in one family K. Tiringer, C. Mori, T. Frischer, A. Zacharasiewicz Department of Pediatrics and Adolescent Medicine, Wilhelminenspital, Vienna, Austria

13

Background:  Cystic fibrosis (CF) is the most common lethal autosomal recessive disorder in childhood. Since the introduction of newborn screening in Austria in 1997, immunoreactive trypsinogen testing (IRT) is performed in newborn blood samples. In case of IRT > 65 ng/ml, retesting is performed in the 4th week of life. If values are still > 50 ng/ml, a sweat test is conducted. Chloride levels < 30 mmol/L are normal, levels between 40–60 mmol/L are in the intermediate range, chloride levels > 60 mmol/L are highly pathological. Genetic testing should be performed as well, however, not all mutations have been described so far, suggesting that a false negative result does not exclude CF. Consequently the diagnostic Gold Standard for CF is still sweat testing. Results:  Here we report three cases of late diagnosed CF in one family. All three sisters had normal newborn screening test results, and were only diagnosed later based on clinical symptoms. Patient 1, a seven year old girl, presented with recurrent pulmonary infections, and therefore underwent sweat testing, which showed pathologic chloride levels. As a consequence, her siblings were tested, revealing pathologic results in her sisters as well. All three sisters displayed aggravated weight gain, diminished elastase in stool, low vitamin A levels and CF-typical pathogens in sputum. Interestingly, patient 1 presented with a subileus directly after birth, and patient 3, a 16 years old girl, had duodenal atresia in infancy and several ileuses. Genetic testing revealed only one mutation in patient 1, however, more detailed analysis is still in progress. Conclusions:  Our cases illustrate the importance of considering CF despite negative newborn screening. False positive as well as false negative results may occur, and also variable sweat test results within one patient may hinder the diagnostic procedure. Diagnosing CF can be difficult! Nevertheless, think CF!

P41 Institutional experience with robotic thymectomy for Myasthenia Gravis J. R. Matilla, B. Moser, W. Klepetko Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria

Background:  Maximal thymus tissue resection is necessary in the treatment of patients with Myasthenia Gravis (MG). To avoid sternotomy several minimal invasive techniques are nowadays avaliable. The aim of this study was to evaluate the left side robotic approach as a safe and accurate option for extended thymectomy. Methods:  Between april 2013 and may 2015, 21 patients recieved left side robotic extended Thymectomy. Median age was 31 and two of them were pediatric cases.Three ports left side approach was carried out with one 13 mm port for the camera on the 5th intercostal space and two 8 mm working ports at 4th and 6th intercostal spaces. Results:  In 20 patients extended thymectomy was carried out, in one patient conversion to sternotomy was needed due to previous pneumonia and lung adhesions to the parietal pleura. No other complications were observed. 135 min was median operative time. All patients were at least 12 h at intensive care unit after the procedure and 3.6 days was median hospital stay. Conclusions:  Da Vinci surgical robotic system enables a very precise disection of all mediastinal structures allowing maximal resection of all thymic and adipose tissue located at the anterior mediastinum. Amount of excised tissue and prompt recovery after surgery are the main two reason we keep using this technique as first therapeutic option for patients with MG. In future studies after 5 years follow up, assessment of neurological improvement accord-

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

827

ÖGP

C-reactive protein serum levels at diagnosis (> 1.0 mg/dL: p < 0.001) and before surgery (> 1.0 mg/dL: p < 0.001), low albumin serum levels before surgery (< 35 g/L: p < 0.001), elevated platelet count before surgery (> 400 × 109/L: p < 0.001) and elevated white blood cell (WBC) count before surgery (≥ 8.3 × 109/L: p = 0.001). Conclusions:  GPS, CRP, albumin, platelet count and WBC count were found to be independently prognostic in patients with MPM in the present cohort. These findings suggest that inflammatory based prognostic markers can be utilized for improved patient selection regarding different therapeutic modalities.

ÖGIM

abstracts

abstracts

ÖGP

ÖGIM

ing to the Myasthenia Gravis Foundation of America classification will be required.

P42

Background:  Children and adolescents are embedded in different social milieus. Smoking is considered to be an individual behavior with personal responsibility. But is that true for teens? Methods and results: 3011 teens completed a questionnaire addressing social factors of smoking conventional cigarettes 2014. Teens 2014

Lung cancer database AKH Linz 2014: news and trends E. Brehm1, T.Gitter2, C.Brock1, B.Lamprecht1  epartment of Pulmonary Medicine, General Hospital Linz, KeplerD University, Linz, Austria 2 Department of Radiology, General Hospital Linz, Kepler-University, Linz, Austria 1

Background:  A lung cancer database is mandatory for the reflection of the own patient population, planning studies, evaluation of therapeutic interventions and quality control. We continued our work of 2013 by including all newly diagnosed lung cancer patients in our patient-customized database for 2014. Methods:  Date of diagnosis, age, gender, family history, topography (C34.×), morphology (ICD-O), staging (pTNM or cTNM by TNM-7), smoking status, lung function parameters and Karnovsky index were recorded. In addition to this, data on therapy and outcome were included with special focus on EGFR-, ALK- and ROS1 status. In the analyses, special attention was dedicated to the cohort of neversmokers with lung cancer. Results:  In 2014, 153 patients were included in the database (C34.0–C34.9), of which 97 are male and 56 female. Age at time of diagnosis ranged from 28 to 89 years, mean age was 67 years. An important aspect of the analysis of 2014 was the concordance with the data of 2013. Both, sex ratio, but also the distribution concerning age, stage and histological classification showed a surprisingly clear reproducibility compared to the year 2013. The data, matched with the smoking status, confirmed a number of previously clinically suspected correlations. On the one hand, neversmokers showed an almost dichotomous sharing with regard to the stage distribution (IA vs. IV). On the other hand, the distribution in the bronchial system was significantly different than in former smokers or current smokers with a clear trend towards increasingly peripheral tumors, especially of the lower lobe (47 % vs. 33 %/31 %). Regarding EGFR and ALK status, we were surprised that—despite reflex testing in a significant proportion of patients (25 % each)—no mutation status was present for various reasons. The group of EGFR mutation-positive patients (2 × Exon 18, 5 × Exon 19del, 1 × Exon 21) confirmed that neither smoking status nor age should be a reason for exclusion from the testing, although, also in our collective, the typical characteristics (female gender, neversmokers) predominated. Conclusions:  These preliminary results allow valuable insights into our patient population. To some extent, this has important clinical impact, and stimulates improvements in quality of patient care.

DR-Smoker

ND-Smoker

DR + ND-Smoker Nonsmoker

Persons in the household Weighted (A)

4,06 (100 %) 4,11 (100 %) 4,06 (100 %)

4,43 (100 %)

Unweighted (UA)

3,94 (100 %) 4,11 (100 %) 3,97 (100 %)

4,26 (100 %)

Smokers in the household Weighted (A)

2,38 (59 %)

1,00 (24 %)

2,22 (55 %)

0,95 (21 %)

Unweighted (UA)

2,38 (59 %)

1,00 (24 %)

2,17 (55 %)

0,78 (18 %)

Smokking within the household Weighted (A)

1,10 (27 %)

0,15 (4 %)

0,89 (22 %)

0,57 (13 %)

Unweighted (UA)

0,78 (19 %)

0,15 (4 %)

0,63 (16 %)

0,38 (9)

DR daily regular, ND not daily smoking. No significant influence on smoking of teens was found by the number of persons in the common household, but with adult smokers in the family. The peer group influences youngsters, too. While nobody is smoking among friends amounts to 22 %, close to 100 % of comrades of smokers puff. Until the age of 20, smoking rises to 48 %, accordingly, the rate of smoking among peers increases to 95 %. Peer pressure is the one, and exposure to smoke the other consequence. There are three educational careers. While there is no difference between “Neue Mittelschule” to secondary vocational college and lower to higher grades of grammar school (“Gymnasium”), the rate of smokers rises from 2 to 15 % during the polytechnical year, and farther to 36 % in the vocational school (“Berufsschule”). Beyond the level of education the monthly disposable money (MDM) plays a significant role in smoking, correlating with r2 = 0.92. During apprenticeship, the MDM averages €  271, in contrast to €  60 during grammar school and € 64 during vocational colleges, at similar age. The final proof of smoking as a social behaviour comes from the finding that males smoke when alone in 19 %, females in 11 %, but when in company, in 81 and 89 % respectively. Conclusions:  During childhood, parental smoking appears to imprint smoking. Secondly, there exists not only a high peer pressure towards smoking, but implicitly an exposure to cigarette smoke as well. More than the educational level and career, the monthly disposable money correlates with regular cigarette consumption, especially related to apprenticeship and its relatively high apprenticeship pay (“Lehrlingsentschädigung”). Smoking appears to be a social behaviour at least during the teens, only about 20 % do not only smoke in company, but also when alone.

P44

P43 The smoking of teens is a social behavoir shaped by environmental factors

Nicotine products used by Upper Austrian teens 2014: E-cigarettes and shisha compared to conventional cigarettes

S. Klade1, B. Lamprecht1, C. Bauer2, P. Flink2, H. Schinko1,2

S. Klade1, B. Lamprecht1, C. Bauer2, P. Flink2, H. Schinko1,2

¹Department of Pulmonary Medicine, General Hospital Linz, KeplerUniversity, Linz, Austria 2 Krebshilfe OÖ, Linz, Austria

1

 epartment of Pulmonary Medicine, General Hospital Linz, KeplerD University, Linz, Austria 2 Krebshilfe OÖ, Linz, Austria

828   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

SHISHA

C-Cig Nonsmoker (%)

(N = 2466; M 50 %, F 50 %) and 2014 (N = 3011; M 63 %, F 35 %) were compared. Strata were: age groups 12–19 + ; types of smokers and schools. The questionnaires asked for daily/weekly consumption, trial and (dis)continuation, the time of the first cigarette after awakening, and attitude towards smoking cessation. Cigarettes

2012 N = 2466 (%)

2014 N = 3011(%)

Change

Never tried

41

40

N.S

C-Cig Smoker (%)

Tried only

33

45

Sig.

7

4

Sig. Sig.

Know

92

99

Not daily ND

Smoking

41

88

Daily regular DR

19

11

2012 (%)

2014 (%)

Tried only

27

3

Smoker ND + DR

Owned

18

50

Age 12

5

0

ESD-E-Cigarette

C-Cig Nonsmoker (%)

C-Cig Smoker (%)

Age 17–18

51

26

95

Age 19+

58

48

Know

75

Smoking

17

34

Tried only

35

13

Owned

5

15

Shisha reveals an age dependent increase of use and possession. While WPs are smoked by 47 % and ESD vaped by 20 %, the possession of shisha by non-smokers surprisingly averages 18 % and of ESD 5 %. The rate of shisha- and ESD-use is twofold in C-Cig-smokers. WPs are smoked less often than 1–2 times/month, ESD vaped several times per week in 15 %, but less often by 52 % of their users. Four fifths of C-Cigs are smoked in company. Shisha and ESD seem to socialize, too. 63 % of ESD-liquids do not contain nicotine, 18 % do so. 38 % of C-Cig-smokers prefer NIC-products, but 51 % vape nicotine-free ones. 12 % of non-C-Cig-smokers enjoy NIC-liquids, they are exposed for the first time to nicotine, thus prone to becoming dependent. The risk of ESD is poorly judged, but the risk of the single WP-use correctly rated as more dangerous than a single C-Cigarette. However, the frequency of daily or weekly C-Cig consumption adds up to a much higher risk. Conclusions:  Shisha and ESD are well known among teens, being appreciated in an age dependent manner like C-Cigs. WPand ESD-use is not seen as a form of smoking. Turning to ESD and shisha seems primarily not to be driven by nicotine, but more likely by social stimuli. Vaping nicotine-free E-cigarettes dominates and could be compared to candy- or chocolate cigarettes, but nicotinecontaining flavours might plaster the way into addiction.

ÖGP

Background:  Conventional cigarettes (C-Cigs) cause harm. In Austria, the habit of smoking shisha is growing. Electronic/electric smoking devices (ESD) are the dominating hype in the USA, surpassing C-Cigs use. The current relevance of shishas (waterpipes WP) and ESD among Upper Austrian teens is unknown. Methods and results:  In 2014, 3011 (Male 55.6 %, F 44.4 %) students of different school types, aged 12–19 + were handed out questionnaires exploring the familiarity, use, and possession of shisha and ESD.

Differences in the three educational careers: Students of grammar schools end up with 7 %, the ones of secondary vocational colleges with 8–9 %, and the apprenticeship-vocational school trainees with 36 % smokers. NDS (not daily smokers) consumed 7.7–8.6 cigs/week, while DRS (daily regular smokers) puffed 9.0–9.7 cigs/day in 2012 and 2014, respectively. Yet, some of the NDS reach a harmful average of 3 or more cigs/day. Most likely due to dependence, 19 % of DRS smoke their first cigarette within 30  min after awakening in contrast to 40–45 % in adults. While 77 % of smoking teens wish to change their habit, approximately 70 % do not want to quit smoking completely. Conclusions:  A decline of not daily and regular smoking was observed in 2014 compared to 2012. The proportion of teens having tried cigarettes, but not continued smoking, increased from 33 to 45 % together with the rate of non-smokers, rising from 74 to 85 % over the last two years. Close to 20 % of daily smokers seem to crave for nicotine. When COPD and lung cancer are smoking-related diseases, their development hypothetically begins with the start of smoking at age 12–19 long before the manifestation of related diseases. The most effective primary prevention would be to avoid taking up smoking already in the teens.

P46 Long-term survival and clinical course after single lung transplantation for interstitial lung disease

P45

C. Haider2, P. Jaksch1, G. Muraköszy1, H. Prosch3, Y. Waseda3, C. Aigner1, G. Lang1, J. Matilla1, W. Klepetko1, C. Lambers1

The smoking habit of Upper Austrian teens has definitely changed between 2012–2014

1

 epartment of Pulmonary Medicine, General Hospital Linz, KeplerD University, Linz, Austria 2 Krebshilfe OÖ, Linz, Austria

 ivision of Thoracic Surgery, Department of Surgery, Medical D University of Vienna, Vienna, Austria 2 Medical University of Vienna, Vienna, Austria 3 Department of Radiology and Nuclear Medicine, Medical University of Vienna, Vienna, Austria

Background:  Smoking is the single most important risk factor for bronchopulmonary, cardio-vascular and neoplastic diseases, shortening life. The beginning of this detrimental habit needs to be explored in detail. Method and results: Subgroup analysis demanded larger numbers of participating teens aged 12–19 + . Results from 2012

Background:  Interstitial lung disease (ILD) is one of the leading causes for lung transplantation (LuTX). Both, Single (SLuTX) and Double (D) LuTX are well established surgical procedures but new data indicate a tendency to favour the latter. Due to a lack of longtime follow-up data, the aim of our study was to evaluate the clinical course in SLuTX for ILD using our single-center data base.

S. Klade1, B. Lamprecht1, C. Bauer2, P. Flink2, H. Schinko1,2

13

1

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

ÖGIM

abstracts

829

ÖGP

ÖGIM

abstracts Methods:  The study was planned as a single-centre, retrospective analysis of 25 patients with histological confirmed UIP (15) or interstitial fibrotic disorders of other reasons (10) who received single-lung transplantation in our centre between 2003 and 2012. The complications analysed using patient charts. High-resolution computed tomography (HRCT) scans pre and post transplant were compared and correlated with lung function parameters over the follow-up period. Statistics were performed using SPSS V 22.0.0.0 Results:  The mean survival of patients after single-lung transplantation was 79.87 ± 8.29 months. Acute rejection (> A2) occurred in 9 of 22 patients (38.5 %) who survived more than 1 year after transplantation and lymphcytic bronchiolitis (> B2) in 7 patients (31.82 %). Severe infections (n = 9; 40.91 %) were associated with either pneumonectomy (n = 4; 2 aspergilloma), re-transplantation (n = 1) or death (n = 4). Malignant diseases were diagnosed in a total of 6 patients (27.27 %) with a median onset of 56 ± 29.83 months. Lung cancer was detected in 3 patients (squamous cell carcinoma (SCC)). Malignancy resulted in a mean survival of 68.74 ± 10.96 months after LuTX, which was statistically significant lower than the survival of patient without malignoma (p = 0.025). Conclusions:  The data provided here suggest that SLuTX might be an appropriate surgical strategy in selected patients suffering from interstitial lung disease.

P47 Quantifying glucose metabolism in isolated ex-vivo perfused marginal donor lungs (EVLP) to assess suitability for transplantation A. Slama, L. Schillab, M. Barta, A. Mitterbauer, S. Schwarz, K. Hoetzenecker, P. Jaksch, W. Klepetko, C. Aigner Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria

Background:  In the past years the EVLP has become a popular method to evaluate marginal donor lungs. However, individual parameters to judge graft quality are still investigated. Donor organ quality could show differences in anaerobic glucose metabolism which might serve as a parameter for decision making during EVLP. Methods:  This study is an analysis of our prospective EVLP database. In the past five years 43 EVLP were performed on initially rejected marginal donor lungs. 28 (65 %) of these lungs were accepted and transplanted with results comparable to standard donor lungs. Absolute glucose consumption and lactate production were calculated and corrected for hourly changes of perfusate and additional glucose administration. These values were compared between accepted (group A) and rejected lungs (group B). Linear regression was performed and the slope values were indexed for donor pTLC to correct for graft size. Results:  Mean EVLP Duration was 275 ± 87  min. (group A, n = 28) vs. 297  min. (group B, n = 15: 238  min; p = 0.039). Subsequently accepted lungs showed a significantly lower total glucose consumption (T1  h: − 899 vs.− 1258  mg; p = 0.29/T2  h: − 1625 vs. − 2293 mg; p = 0.058/T3 h: 2432 vs. − 3380 mg; p = 0.015/T4 h: − 2812 vs. − 4771 mg; p < 0.001) and lower lactate production (T1 h: 7.5 vs. 9.5  mmol; p = 0.44/T2  h: 15 vs. 19.6  mmol; p = 0.09/T3  h: 22.3 vs. 29 mmol; p = 0.02/T4 h: 27 vs. 42.7 mmol; p < 0.001). In linear regression analysis glucose consumption and lactate production slopes were significantly different between the groups (glucose: − 2.03 ± 1.03 vs. − 3.06 ± 1.41  mg/min/LTLCp; p = 0.021/lactate: 0.019 ± 0.008 vs. 0.028 ± 0.013 mmol/min/LTLCp; p = 0.038. Furthermore, lactate and glucose slopes were significantly correlated(r = − 0.798; p < 0.001).

Conclusions:  Lactate and glucose changes are linear and highly correlated in isolated perfused lungs. As the production of lactate and the consumption of glucose is significantly higher in unacceptable donor lungs, these parameters should be an important part of the decision making process during EVLP of marginal donor lungs.

P48 Real-life experience and clinical characterization in patients with NSCLC harbouring an ALK rearrangement: a multicentre study S. Holzer1, M. Hochmair1, U. Setinek1, A. Mohn-Staudner1, K. Kirchbacher2, I. Kapfhammer1, B.-M. Arns3, A. Valipour1, G.-C. Funk1, O. C. Burghuber1  epartment of Respiratory and Critical Care Medicine, Otto Wagner D Hospital, Vienna, Austria 2 Department of Internal Medicine II (Pneumology), Wilhelminenspital, Vienna, Austria 3 Department of Pneumology, Landeskrankenhaus Hochegg, Grimmenstein, Austria 4 Department of Pneumology, Hospital Hietzing, Vienna, Austria 1

Background:  ALK translocations, occurring in 3–5 % of patients with NSCLC (non-small cell lung cancer), have improved the treatment for these patients. We examined the clinical characteristics, diagnostic modalities and treatment outcomes of these ALK + NSCLC patients. Methods:  Data from patients with adenocarcinoma and NSCLC/NOS (Not Otherwise Specified) whose tumors were routinely analysed for EML4-ALK were reviewed. Patient characteristics including age, sex, race, smoking history, localization of biopsy, response to ALK Inhibitors and presence/absence of brain metastasis were collected. All data were obtained from 4 hospitals in Austria with high expertise in the management of lung cancer from August 2011 till October 2014. EML4-ALK was identified by a twostep procedure. First an immunohistochemical staining was done with the Ventana anti ALK (D5F3), Opti View DAB IHC DetectionKit and Opti View Amplifikation Kit®. Further on weak to strong positive cases were tested by ALK FISH (dual colour breakapart FISH/ Abbott Vysis®). Results:  1756 consecutive patients were tested for EML4-ALK mutation. EML4-ALK positive immunohistochemical staining was found in 228 patients (13 %). 39 of these patients (2.2 %) showed positive ALK FISH analysis. However 2 patients with strong immunohistochemical staining showed no rearrangement in FISH analysis. These 2 patients were also treated with an ALK Inhibitor and showed tumour shrinkage. From these EML4-ALK translocation positive 41 patients, 25 patients were women and 16 men. 26 patients (63 %) were never smokers, 9 were former smokers (22 %) and 6 smokers (15 %). Biopsies were taken in 26 patients from the primary tumor and in 8 patients from the lymph nodes, in 6 patients the analysis was performed by drainage of pleura effusions and in 1 patient by drainage of a pericardial effusion. 26 patients received an ALK Inhibitor. 6 patients had a complete response, 19 patients a partial response, 0 patients a stable disease and 1 patient showed a progressive disease. 15 patients did not receive an ALK Inhibitor, because they were not in an advanced stage. Data showed that 8 patients developed brain metastasis during treatment with an ALK Inhibitor, 5 patients had initial brain metastasis and 28 patients had no brain metastasis. Conclusions:  ALK rearrangements are observed in 2.2 % of Adenocarcinoma and NSCLC/NOS. It can be detected in all patients independent of any clinical characterization and/or smoking

830   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

abstracts behaviour. Therefore, reflex testing is recommended, since patients treated with an ALK Inhibitor had a clear benefit from treatment.

P50

EGFR resistant T790M mutation in NSCLC: real-life data of patients treated with AZD9291 M. Hochmair1, S. Holzer1, U. Setinek1, M. Filipits2, A. Mohn-Staudner1, M. Korger3, H. Fabikan1, C. Pirker1, O. C. Burghuber1  epartment of Respiratory and Critical Care Medicine, Otto Wagner D Hospital, Vienna, Austria 2 Department of Medicine I, Medical University of Vienna, Vienna, Austria. 3 Department of Internal Medicine II, Hospital of Barmherzige Brüder, Eisenstadt, Austria 1

Background:  Somatic mutations in epidermal growth factor receptor (EGFR) are detected in 12,6 % of the Austrian non-small cell lung cancer (NSCLC) patients [1]. The EGFR T790M Mutation located on Exon 20 is the most common mechanism of drug resistance to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutated NSCLC patients [2]. There is no documented clinical experience with the T790M Inhibitor in Austria. Methods:  We administered AZD9291, a 3rd generation EGFRTKI which is also active in tumours harbouring the T790M Mutation, to 4 patients who had disease progression after previous treatment with an EGFR TKI. We are provided with the EGFR inhibitor AZD9291 by AstraZeneca for patients without further treatment options (compassionate access), who had several lines of therapy. In two patients the T790M mutation was detected by re-biopsy of the tumor tissue (pleura effusion, supraclavicular lymph node) and in two patients by liquid biopsy. Blood samples were collected in EDTA Vacutainer tubes. Neutral buffered formalin solution was added immediately. DNA extraction was done with the DNA Sample Preparation Kit Roche®. Mutation testing was performed with the COBAS 4800 EGFR Mutation Test Kit ®. All 4 patients had already at least 2 lines of chemotherapy and 1 EGFR TKI. Treatment start with AZD9291 was between May and June 2015. Results:  All 4 patients showed a clear clinical and radiographic improvement and 2 patients showed a complete remission after treatment with AZD9291. There are no reports of side effects after clinical application of AZD9291. Conclusions:  AZD9291 was highly effective in our patients, while showing good tolerability. Therefore re-biopsy (tumor tissue or liquid biopsy) should be performed in clinical practice to detect the T790M Mutation. Liquid biopsy is more convenient to the patients and could replace the re-biopsy in clinical practice in the future. References 1. Hochmair MJ et al. EGFR, EML4-ALK and ROS 1 testing in Austrian patients with NSCLC: a multicentre study. Translational Lung Cancer Research. 2014;3:5. 2. Jänne PA et al. AZD9291 in EGFR Inhibitor-Resistant Non-SmallCell Lung Cancer. N Engl J Med. 2015;372:18.

G. Seebacher1, O. Kuhtin2, S. Decker2, V. Haas2, H. J. Schäfers3, J. R. Fischer4, T. Graeter2  epartment of General and Thoracic Surgery, Private Medical D School Krems, Krems, Austria 2 Department of Thoracic and Vascular Surgery, Klinik Löwenstein, Löwenstein, Germany 3 Department of Thoracic, Cardiac and Vascular Surgery, Saarland University, Saarbrücken, Germany 4 Department of Oncology, Klinik Löwenstein, Löwenstein, Germany 1

Background:  Bronchial sleeve resection in non small cell lung cancer (NSCLC) is often required to avoid pneumonectomy in central tumors. Close resection margins are sometimes inevitable. To avoid local recurrence, adjuvant radiotherapy is frequently considered. But is it worth while? Methods:  We retrospectively evaluated 199 consecutive patients after bronchial sleeve lobectomy of NSCLC. Complete resection was demonstrated for all of them by pathology. Indication for radiotherapy was a resection margin lesser 2 mm to the tumor or N2 disease. We formed two groups, group 1 received adjuvant radiotherapy and group 2 did not. Group 1 consisted of 64 patients with different tumor stages (IIB: n = 9; IIIA: n = 33; IIIB: n = 22) compared to group 2 consisting of 135 patients (IA + IB: n = 45; IIA + IIB: n = 45; IIIA: n = 28; IIIB: n = 9; IV: n = 8). Therefore the groups were not fully homogenous. The dosage of radiotherapy was 45–61 Gy. Results:  Local recurrence was seen in 2 patients in group 1 (3.1 %) and in 2 patients in group 2 (1.5 %) (p = n.s.). Complications concerning the healing of the bronchial anastomosis were seen in 7.8 % (n = 5) in group 1 compared to 5.9 % (n = 8) in group 2 (p = n.s.). Distant metastases were observed in 51.5 % (n = 33) and 43.7 % (n = 8) respectively (p = n.s.). 2 and 5 years survival was 77 and 57 % in group 1 and 83 and 65 % in group 2 (p = n.s.). In stage IIIA survival was as well not significant in both groups, 60 % (n = 33) versus 71 % (n = 28). Difference in 5 year survival in patients free from N2 disease was 50 % (n = 14) in group 1 and 69.8 % (n = 90) in group 2 (p = n.s.). Conclusions:  Adjuvant radiotherapy had no negative effect on healing of the bronchial anastomosis. Despite of adjuvant radiotherapy, the rate of local recurrence was slightly elevated. Especially in patients with close resection margins the positive effect of adjuvant radiotherapy is doubtful.

P51 Clinical relevance of pharmacologic testing during right heart catheterization V. Foris1,2, G. Kovacs1,2, P. Douschan1,2, X. Kqiku2, C. Hesse2, G. Bachmaier3, A. Avian1,3, A. Olschewski1,4, H. Olschewski1,2 Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria 2 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 3 lnstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria 4 Experimental Anesthesiology, Department of Anesthesia and Intensive Care Medicine, Medical University of Graz, Graz, Austria 1

Background:  In patients with pulmonary arterial hypertension (PAH) nitric oxide (NO) is used for acute vasoreactivity testing.

13

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

831

ÖGP

P49

ÖGIM

Evaluation of adjuvant radiotherapy after bronchial sleeve resections for non small cell lung cancer

ÖGP

ÖGIM

abstracts However, little is known about the acute effects of sildenafil and iloprost and their relationship to the effects for NO. Aims: 1. to assess the maximal vasodilatory response in patients with pulmonary hypertension (PH) and its relationship with baseline hemodynamics 2.  to assess the change in pO2 during pharmacologic testing 3. to compare hemodynamic changes to NO, sildenafil and iloprost in different subgroups of PH (PAH and nonPAH-PH). Methods:  We analyzed retrospectively all patients undergoing right heart catheterization and pharmacologic testing with NO (15 ppm), sildenafil (50 mg) and iloprost (5 ug) between 2006 and 2014 in our center. Known NO responders were excluded. Hemodynamic responses were evaluated at baseline, during NO inhalation, 60  min after sildenafil intake and 5  min after inhalation with iloprost. Maximal vasodilatory response was defined as the change in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) after iloprost inhalation as compared to baseline. Data are expressed as mean ± standard deviation. Results:  We included n  =  111 PH patients (age: 64  ±  14 yr, females/males: 62/49, meanPAP: 44.5 ± 12.2  mmHg, PVR: 8.3 ± 4.7 WU). Maximal vasodilatory response revealed a 20.2  ±  10.2  % decrease in mPAP and 28.3 ± 14.1 % decrease in PVR. This response was only moderately associated with baseline hemodynamics (r = −0.35, p = 0.0002 for mPAP; r = − 0.16, p = 0.03 for PVR). The change in pO2 was independent from baseline mPAP (r = 0.16, p = NS) and PVR (r = 0.11, p = NS). During NO inhalation, mPAP decreased by 4.5 ± 4.9 mmHg (p < 0.008) and showed a comparable response to sildenafil (- 5.8 ± 4.4  mmHg, p < 0.0005) in the whole study population. The mPAP response to NO inhalation was strongly correlated with the response to sildenafil in PAH patients (n = 37, r = 0.67, p < 0.0001) and moderately in nonPAH-PH (n = 74, r = 0.34, p < 0.003). The same tendency was observed for iloprost as well. Conclusions:  Maximum vasodilatory response in patients with PH was in average 20 % with large individual variability and was only moderately associated with baseline hemodynamics, challenging the concept of a vasoconstrictive disease turning into a “fixed” vasculopathy with disease progression.

P52 Pulmonary rehabilitation: a tool to improve patients with COPD? G. Seiwald1, A. Spary2, A. Dorr2 Pensionsversicherungsanstalt, Vienna, Austria Zentrum für ambulante Rehabilitation der Pensionsversicherungsanstalt Graz, Graz, Austria

1 2

Background:  Pulmonary rehabilitation is a proven and recommended therapy in patients with chronic obstructive pulmonary disease (COPD). Rehabilitation should last 6 to 12 weeks. Two different settings, for 6 weeks (Phase II) and 6 month (Phase III) respectively, are offered in the outpatient rehabilitation centre in Graz (ZAR Graz), consisting of a program according to the guidelines on pulmonary rehabilitation in adults. Methods:  From 2011 to 2014, 72 patients underwent pulmonary rehabilitation, 38 with COPD, 16 with stable asthma and 18 suffering from other pulmonary diseases. Not all of them performed the scheduled mandatory 6 min walk test (6MWT) at beginning and the end of rehabilitation period. Results:  25/38 COPD patients could be evaluated by 6MWT at the beginning and the end of rehabilitation. Patients with COPD improved their walking distance at an average of 43.6 meters (− 54.5

to + 190  m). Phase II patients could improve more than Phase III patients (59.5 vs 9.7 meters leading from − 54.5 to 190 and from − 58.5 to 83.9 respectively). Taking regard on the MCID (minimal clinical important difference) witch is supposed to be more than 50 meters improvement in the 6 min walk test, only 9/17 patients with COPD during Phase II and only 1/8 after Phase III reached that goal. Conclusions:  In our institution rehabilitation in patients with a variety of pulmonary diseases leads to a moderate benefit regarding the MCID criteria. This might be caused by respiratory infections with exacerbation of COPD during rehabilitation. Nevertheless they do improve their fitness and therefore manage their everyday work easier. As a consequence pulmonary rehabilitation should be offered to patients with COPD and is a treatment arm additionally to bronchodilatators and glucocorticoids.

P53 Lung clearance index measurement coming of age F. Singer1, N. Berg2, J. Engel2, H. Schulz3, K. Husemann2, M. Kohlhaeufl2 University Children’s Hospital Zurich, Zurich, Switzerland Klinik Schillerhoehe, Robert-Bosch-Krankenhaus, Stuttgart, Germany 3 Institute of Epidemiology, Helmholtz Zentrum Munich, Munich, Germany 1 2

Background:  Lung clearance index (LCI) derived from multiple-breath washout (MBW) is an established proxy of small airways function in children with cystic fibrosis (CF). Yet, LCI measurements using a validated and available MBW setup and protocol have not been systematically studied in adults with prevalent chronic lung diseases. Methods:  In a tertiary care center, 20 outpatients with asthma, 20 with COPD, and 14 with CF performed spirometry and nitrogen MBW using the ExhalyzerD. LCI was analysed at 2 MBW endpoints: at 1/40th (standard) and earlier at 1/20th (shortened) of starting nitrogen concentration. Outcomes were (i) prevalence of abnormal FEV1 and standard and shortened LCI (± 1.96 z-scores), (ii) agreement between LCIs and (iii) time savings achieved by the shortened protocol. Results:  FEV1 and LCI were abnormal in 26/54 (48 %) and in 40/54 (74 %) patients, respectively. Stratifying into the disease groups asthma, COPD, and CF, FEV1 was abnormal in 3/20, 15/20, and 8/14; LCI2.5 was abnormal in 10/20, 17/20, 13/14, respectively. Agreement of standard and shortened LCI in categories normal vs. abnormal was excellent, Kappa = 0.81. Mean (SD) or average percent time savings were 280 (120) seconds (s) or 33 %, 540 (300) s or 43 %, 630 (440) s or 48 %. Conclusions:  Despite normal spirometry, LCI detects abnormal lung function in 26 % of patients with obstructive lung diseases. Shortened LCI measurement is reliable and may increase feasibility in an outpatient setting due to considerable time savings.

P54 Foster® NEXThaler®: effectiveness and satisfaction in daily asthma treatment W. Popp Department of Pneumology and Center for Long-term Ventilation, Geriatric Centre am Wienerwald, Vienna, Austria

832   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

P55 Are doctors familiar with the test characteristics of lung cancer screening? R. Schmidt, R. Breyer-Kohansal, G. C. Funk Department of Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna, Austria

Background:  Screening with low-dose CT scan can prevent three deaths due to lung cancer among 1000 high-risk individuals. However, false-positive results and radiation exposure are relevant disadvantages deserving accurate consideration. Candidates for screening can only make an autonomous decision if doctors inform them correctly about the pros and cons of the method. Therefore, this study aims to evaluate, whether doctors understand the test characteristics of lung cancer screening. Methods:  In a randomized trial, 556 doctors (members of the Austrian Respiratory Society) were invited to answer questions regarding lung cancer screening based on online case vignettes. Half of the participants were randomized to the group ‘with solutions’ and received the correct solutions in advance. The group ‘without solutions’ had to rely on prior knowledge or estimate. Primary endpoint was the between-groups difference in the estimated number of deaths preventable by screening. Secondary endpoints were the between-groups differences in prevalence of lung cancer, prevalence of suspicious results, sensitivity, specificity, positive-predictive value, and false negative rate. Estimations were also compared to actual values from the literature. Results:  The response rate was 29 % in both groups (80 ‘without solutions’, 81, ‘with solutions’, respectively). Reduction of number of deaths due to screening was overestimated six-fold (95%CI: 4–8)

13

with no effect of group allocation. Providing the correct solutions to doctors had no systematic effect on their answers. Compared to actual values from the literature the prevalence of lung cancer was overestimated three-fold, while the prevalence of suspicious results, specificity, positive-predictive value, and false-negative rate were underestimated. Conclusions:  Doctors poorly understand the test characteristics of lung cancer screening. Offering the correct solutions in advance did not improve the answers. Continuing education about lung cancer screening as well as interpretation of test characteristics might be simple remedies.

P56 Moderate intensity continuous versus high intensity interval treadmill walking in patients with severe COPD: a pilot feasibility study T. Schneeberger1, R. Gloeckl1, I. Heinzelmann1, S. Adler2, T. Damisch1, A. Jerrentrup2, K. Kenn1  epartment of Respiratory Medicine, Schoen Klinik D Berchtesgadener Land, Schoenau am Koenigssee, Germany 2 Department of Internal Medicine, University Hospital Marburg, Marburg, Germany 1

Background:  It has been shown that patients with severe chronic obstructive pulmonary disease (COPD) perceive lower levels of dyspnea during interval cycling training compared to continuous cycling. In this pilot study we investigated if interval walking training is also feasible on a treadmill and if patients also show lower levels of dyspnea. Methods:  20 COPD patients (age: 62 ± 10 ys, FEV1: 37 ± 15 % pred.) were enrolled in this prospective, randomized study. All patients underwent a 3-week inpatient pulmonary rehabilitation (PR) program including a standardized exercise training with strength training and treadmill walking on 5 days per week. For the treadmill walking program patients were randomly assigned to either a moderate intense continuous group (MIC) walking at a speed of 60 % from mean baseline 6-minute walking test (6MWT) speed or a high intensity interval (HIT) group exercising at 120 % of mean 6MWT speed for 1 min alternating with 1 min of rest. Ratings for dyspnea (primary outcome) and leg fatigue on a 10-point Borg scale, heart rate and oxygen saturation were recorded during each session. Results:  6 MWD improved significantly (p < 0.001) in both groups without any significant between-group difference (MIC: 40 ± 41 m and HIT: 35 ± 19 m). Chair-rise-test improved significantly only in the HIT-group (− 2.5 ± 1.7  s, p = 0.003) but not in the MICgroup (− 1.3 ± 1.4  s, p = 0.051). Patients in the HIT-group showed the tendency of lower levels of dyspnea (Borg scale: 3.5 ± 1.0 versus 4.2 ± 1.4) and comparable leg fatigue (Borg scale: 2.6 ± 1.4 versus 2.7 ± 1.8) during exercise. Also mean oxygen saturation and heart rate were comparable between both exercise modalities. Conclusions:  To our knowledge this pilot study was the first to investigate interval walking training on a treadmill in patients with severe COPD. It seems that MIC and HIT treadmill walking are both feasible exercise modalities. Adequately powered studies are needed to detect possible differences in physiological response and training effects.

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

833

ÖGP

Background:  DPIs are important inhalation devices in asthma bronchiale therapy. However, it is known from daily practice and several studies that DPIs are often incorrectly used leading to negative impact of therapeutic success. Aim of this NIS was to evaluate effectiveness and handling of Foster® NEXThaler®. Methods:  A prospective, multicenter, non-interventional study (NIS) was conducted in pulmonary and general practices in Austria in 2014. Asthmatics treated with a fixcombination of extrafine 100  mg beclomethasone/6  mg formoterol delivered via NEXThaler® device (DPI) were monitored over 12 weeks (3 visits). Lung function, symptom scores, exacerbations as well as satisfaction, adherence and tolerability were recorded. At baseline and last visit the patient check was performed to determine asthma control status (GINA check). Results:  175 patients (male 43 %, mean age 53 years) were analysed. Asthma control, lung function (PEF, FEV1 and FVC) and symptom scores improved significantly (p < 0.001), the exacerbation rate decreased significantly (p < 0.001) from 31 to 3.8 % after 12 weeks of treatment with Foster® NEXThaler®. A significant improvement of GINA score was seen in all patients (from 3.1 to 1.2 after 12 weeks; p < 0.001) and even in patients pretreated with ICS/LABA fixcombinations (p < 0.001). According to the physician’s assessment 85.9 % of the patients were highly/very satisfied with the use of Foster® NEXThaler® and 97.4 % assessed the handling as very good/ good. Consequently, 93.3 % of the patients wished to continue with Foster® NEXThaler®. Three non-serious cases of adverse reactions were reported (dysphonia, tremor and pruritus). Conclusions:  The results showed effectiveness of treatment with Foster® Nexthaler®, improvement in asthma control, decreasing asthma symptoms and exacerbations and increasing of lung function parameters. Treatment was well tolerated and lead according to the physicians’ opinion to very satisfied patients.

ÖGIM

abstracts

abstracts

ÖGIM

P57 Differences in pulmonary rehabilitation outcomes in patients after single or double lung transplantation

ÖGP

T. Schneeberger, R. Gloeckl, B. Sczepanski, S. Winterkamp, K. Kenn Department of Respiratory Medicine, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany

Background:  PR following LTx can almost be seen as an established therapeutic modality. However, differences concerning the efficiency of pulmonary rehabilitation (PR) in patients with single (SLTx) or double (DLTx) lung transplantation have barely been studied yet. Methods:  In a retrospective analysis (period: 1997–2013) 550 patients with COPD or interstitial lung diseases after LTx (SLTx: n = 212, FEV1 55 ± 18 % pred., age: 58 ± 6 ys; DLTx: n = 338, FEV1 70 ± 19 % pred., age: 53 ± 8 ys) were included. All patients underwent a standardized inpatient PR program of about 41 ± 18 days in average. Data of 6-minute walking distance (6MWD), health related quality of life (physical [PCS] and mental [MCS] component summary of the SF 36 questionnaire) and adverse events during PR have been registered and analyzed. Results:  In SLTx patients, 6MWD increased from 267 ± 134 to 381 ± 120 (p < 0.001), PCS from 32 ± 9 to 39 ± 10 and MCS from 40 ± 17 to 48 ± 15 (p < 0.001 each). In DLTx patients, 6MWD increased from 284 ± 144 to 412 ± 126, PCS from 27 ± 11 to 35 ± 10 and MCS from 41 ± 16 to 50 ± 14 (p < 0.001 each). DLTx patients improved their 6MWD significantly (p = 0,045) more than SLTx patients. Benefits in HRQL were statistically comparable in patients with SLTx and DLTx (p = n.s.). Frequency of adverse events was similar in both groups (bacterial infection [SLTx 16.5 % vs. DLTx 20.4%]; virus infection (cytomegaly) [SLTx 13.2 % vs. DLTx 9.2%]; all p = n.s.). Conclusions:  These results show that patients benefit significantly and clinically relevant from a comprehensive PR program performed immediately after surgery. With regard to the improvements in HRQL, or frequency of complications during PR, there was no statistically difference. However exercise capacity improved significantly more in patients after DLTx.

P58 Clinical impact of nonsteroidal anti-inflammatory drugs on the recurrence rate of pneumothoraces M. Fediuk, A. Striessnig, M. Besenbaeck, N. Fink-Neuboeck, J. Lindenmann, F. M. Smolle-Juettner Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, Graz, Austria

Background:  Spontaneous pneumothorax is not uncommon. In 2013, 710 patients were diagnosed with spontaneous (tension) pneumothorax in Austria. There are many causes for recurrence and not all of them are identified yet. It has been proven that nonsteroidal antiinflammatory drugs (NSAIDs) lead to reduced efficacy of pleurodesis by attenuation of the inflamm-atory process. The effect of NSAID administration on the recurrence rate is barely investigatet yet. The aim of this study was to prove a correlation between the recurrence rate of spontaneous pneumothorax and the dose of NSAIDs. Methods:  The quantity (mg), duration (days), substance as well as the time of ad-ministration (pre- or postoperative) of NSAIDs

were analysed in 133 patients in this retrospective single-center study. The patients were divided into two goups. Patients that sustained a short-term recurrence of pneumothorax within 14 days were enrolled in the first goup (N = 25). The second group included all patients that had not sustained a recurrent pneumothorax during this period. (N = 108). Data were compared and analysed by the two-sample t-test (p ≤ 0.05). Results:  No correlation between quantity, duration, substance, time of administration and short-term recurrence rate (within 14 days) could be detected. Conclusions:  The results of this study could not justify the avoidance of NSAIDs perioperatively. Nevertheless, the influence of NSAIDs on the quality of pleurodesis should be considered and needs further investigation.

P59 Management of necrotising pneumonia in a toddler A. Pfleger1, R. Ulreich1, L. Stroedter2, G. Zobel1, E. Eber1  epartment of Paediatrics and Adolescent Medicine, Medical D University of Graz, Graz, Austria 2 Department of Paediatric and Adolescent Surgery, Medical University of Graz, Graz, Austria 1

Background:  Complications in childhood pneumonia include pleural effusion, empyema, lung abscess, pneumatocele and necrotising pneumonia (NP), also named cavitatory pneumonia. NP is an uncommon complication but its incidence is increasing [Spencer et al. Paediatr Respir Rev 2014]. Methods:  We report on a 3-year-old girl with pneumonia and pleural effusion. The complicated disease course and management are presented. Results:  The child presented with dyspnoe, hypoxia and diminished breath sounds over the left thorax and a red skin rash. Chest x-ray showed pneumonia in the left lower lobe and significant pleural fluid; laboratory values revealed leukopenia, hyponatremia and CRP 215 mg/l, PCT 310 ng/ml, IL - 6 > 5000 pg/ml. Intravenous amoxicillin-clavulanate was started and a small-bore pigtail catheter inserted. In both drain fluid and a throat swab Streptococcus pyogenes was identified. After three days pleural drainage and urokinase instillation with clinical and laboratory improvement the girl again developed fever, and CRP and leucocytes increased (50.000/ml). Ultrasound and x-ray showed a large pleural effusion and opacification of the left hemithorax. Bronchoscopy excluded a foreign body, VATS was performed, a chest drain placed and antibiotics changed to clindamycin and ceftriaxon according to the antibiogram. After clinical and laboratory improvement again subfebrile temperatures and elevated CRP was detected. Chest CT showed loss of normal parenchymal architecture in parts of the left lung; BAL revealed no other pathogens. After a prolonged antibiotic course of 5 weeks a gradual and steady improvement could be achieved. A 4 weeks follow up showed excellent results. Conclusions:  Management of NP includes conservative and surgical measures and may be difficult. Despite the severity of the illness, outcomes are excellent.

834   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

Product failures in home care respirators and corresponding risk for patients: analysis of field safety notes published by the BfArM 2005–2013 J. Hannig, R. Siekmeier Drug Regulatory Affairs, Pharmaceutical Institute, University Bonn, Bonn, Germany

Background:  Marketing and post market surveillance of medical devices in the European Economic Area is regulated by the European Directive 93/42/EEC. In cases of incidents and field safety corrective actions (FSCA) manufacturers have to inform responsible Competent Authority (D: BfArM, AU: BASG) and public by field safety notices (FSN). Here we studied FSN for home care respirators in respect to the MEDDEV 2.12–1 rev 8. Methods:  FSCA and FSN published by BfArM 2005–2013 (http://www.bfarm.de/DE/Medizinprodukte/riskinfo/kundeninfo/functions/kundeninfo-node.html) for the included products were analyzed. Results:  Of 18 published FSCA German and English FSN were found in 18/13 cases, respectively. FSN were clearly characterized as FSN in 12/9 or declaration of type of action in 13/9 cases, respectively. Product names, detailed information regarding FSCA and product malfunction were found in all German and English FSN. Lot numbers or other information for product characterization were available in 1/1 and 9/7 cases. Information on product related risks with previous use of affected devices was provided in 13/10 cases and in 17/13 cases manufacturers provided information to mitigate product related risks. Comments or descriptions playing down the risk were found in 3/2 cases. Typical types of product malfunction were software errors (6/4 cases), issues with electrical components (7/7 cases) and error in production (3/1 cases). Most frequent product related risks were erroneous ventilation or stop of therapy (5/3 cases) and fire hazard including burn (2/2 cases). Reported measures for risk mitigation were stop of use, product destruction or quarantine (4/3 cases), additional recommendations for use (2/2 cases) and others (8/7). Conclusions:  Most FSN fulfil the MEDDEV criteria and include sufficient information on FSCA, type of product failure and corrective measures. However, due to their importance for reduction of product related risks in FSCA type and content of FSN should be further improved.

P61 The influence of inflammatory parameters and tumorous lymphatic vessel invasion on the postoperative survival in resected early stage nonsmall cell lung cancer A. Striessnig, M. Fediuk, F. Spitzer, N. Fink-Neuboeck, J. Lindenmann Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, Graz, Austria

Background:  There is clinical evidence that inflammation accelerates tumor growth followed by reduced survival in patients with cancer. The aim of this study was done to evaluate the clinical impact of preoperatively measured inflammatory parameters and the incidence of lymphatic vessel invasion on the postoperative sur-

13

vival in patients with resected non-small cell lung cancer (NSCLC) Stage I. Methods:  For this retrospective data analysis, 741 patients who had undergone lung surgery due to lung cancer from 01.01.2003 to 31.12.2011 were assessed. However 156 patients met the inclusion criteria and were therefore considered for statistical evaluation. Results:  53 patients (34  %) showed preoperatively elevated CRP levels. Elevated leucocytes levels and hypoalbuminemia were detected in only 9 cases (5.8 %). 110/156 patients (70.5 %) had GPS 0, 45 (28.8 %) had GPS 1 and only 1 patient had GPS2. The inflammatory parameters showed no statistical significance. The 5-year-overall survival (OS) was 74 %, 3-year and 1-year-OS were 79 and 95 %. However, 5-year-progression free survival (PFS) was 79 %, 3-year and 1-year-PFS yielded 84 and 96 %, respectively. A significant difference was detected between PFS and patients with lymphatic vessel invasion (p = 0.026), as well as CSS (Cancer specific survival) (p = 0.015). Lymphovascular tumor invasion is accompanied by a higher recurrence rate (p = 0.032), a significant lower progression free survival and a significant lower cancer specific survival. Conclusions:  The expected prognostic impact of those inflammatory parameters on the postoperative survival of patients with curatively resected NSCLC stage I, could not be confirmed in this retrospective data analysis. On the other hand the histologically verified tumorous lymphatic vessel invasion has proven to serve as a prognostic independent parameter in this very collective and should be therefore taken into account when the decision concerning possible adjuvant therapy has to be made.

P62 Torque Teno virus kinetics after lung transplantation and its association to immunosuppression schemes and to clinical complications P. Jaksch1, I. Goerzer2, G. Muraközy1, C. Lambers1, T. Seitz2, W. Klepetko1, E Puchhammer-Stöckl2 ¹Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria ²Department of Virology, Medical University of Vienna, Vienna, Austria

Background:  We have shown previously that the plasma DNA level of human Torque Teno virus (TTV), a virus which is widespread in the population and causes persistent DNAemia in the absence of any defined disease, is associated with immunosuppression in lung transplant recipients (LTRs). We now investigated the correlation of TTV DNA with different immunosuppressive schemes, and with the occurrence of clinical complications. Methods:  Plasma TTV-DNA loads were analyzed at defined intervals within one year post transplantation by quantitative real-time PCR in 44 LTRs, receiving induction therapy with either Alemtuzumab (Campath) (n = 26) or with ATG (n = 12) or received no induction therapy (n = 6). The TTV load was further compared to clinical data. Results:  The TTV-DNA load significantly increased in all cases post transplantation within the first 60–90 days and remained at high levels thereafter. The TTV-DNA load reached significantly higher levels in patients receiving induction therapy with Campath (p < 0.001). In 25 patients episodes of microbial infections occurred within the first year after transplantation. The patients’ mean TTV DNA load prior to these episodes was significantly higher than that in 19 control patients without infections at the same time period (p = 0.002). Conclusions:  Induction therapy with Campath seems to result in higher immunosuppression, reflected by TTV-DNA load post transplantation. Furthermore, it was confirmed that high

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

835

ÖGP

P60

ÖGIM

abstracts

abstracts

ÖGP

ÖGIM

plasma TTV- DNA load is related to the development of microbial infections.

P63 Coincidence of type 2 diabetes, hypertension, obesity and sleep related breathing disorders in a department of internal medicine M. Blaukovitsch, W. Auer, B. Jeschek, V. Stepan Department of Internal Medicine, Krankenhaus der Elisabethinen Graz, Graz, Austria

Background:  Sleep related breathing disorders (SRBD) and their cardiovascular consequences have been described in several studies. There is strong evidence of a positive relationship between SRBD and hypertension, stroke and heart failure. A fever studies

have been published to evaluate the prevalence of type 2 diabetes and cardiovascular risk factors in the co- appearance of SRBD. Methods:  We analyzed medical records of our patients for diabetes type 2, hypertension and SRBD measured with standard 5-channel polygraphy. In addition we evaluated patient’s medical history for heart failure, atrial fibrillation, amount of antihypertensive drugs, body mass index, HbA1c% and apnoea-hypopnoea index (AHI). Results:  127 patients underwent polygraphic sleep testing in the last 12 months in the department of internal medicine. 71 (39 male/32 female) suffered from diabetes type 2 and/or hypertension, respectively. 29 patients had type 2 diabetes with an HbA1c greater than 6.5 %, were treated with 3 or more antihypertensive drugs and were concomitantly obese with a BMI greater than 29 kg/m2. 26 of those 29 patients (90 %) were diagnosed with a SRBD (mean AHI 26/h). Conclusions:  The high prevalence of SRBD in hypertensive, obese patients and those resistant to antihypertensive therapy and requiring intensive diabetes therapy highlights the need for effective screening and diagnosis of SRBD in this special patient population.

836   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

13

Autorenverzeichnis

Autorenverzeichnis

B Bachmaier, G. P 51 Bálint, Z, P 27 Bálint, Z. P 01, P 09 Barta, M. P 05, P 47 Bauer, C. P 43, P 44, P 45 Baumer, H. P 33 Baumgartner, B. P 33 Bekos, C. P 02, P 12 Bellmann-Weiler, R. P 18 Benesch, M. F 08 Berg, N. P 53 Berger, W. P 03, P 14 Bertsch, A. P 13 Besenbaeck, M. P 58 Biasin, V. P 15 Bigenzahn, W. P 36 Bitterlich, E. P 33 Blaukovitsch, M. P 63 Blazek, G. P 33 Bolitschek, J. P 33 Bratkovskis, M. P 23 Braz, P. F 01 Bredies, K. P 09 Brehm, E. P 42 Breyer-Kohansal, R. P 55 Brock, C. P 42 Brodowicz, T. F 07 Bucher, B. F 11 Burghuber, O. C. P 24, P 48, P 49

C Cerkl, P. P 26, P 33 Chorostowska-Wynimko, J. P 07 Crnkovic, S. P 19 Crnkovic. P 16

D Damisch, T. P 56 Darwisch, M. P 28

13

E Eber, E. F 08, P 59 Eckmayr, J. F 04, P 26, P 33 Egemnazarov, B. P 16, P 19 Eibl, M. P 29 Eisenberger, H. F 02 Engel, J. P 53 Enzenberg, U. P 28 Errhalt, P. F 09, P 33, P 38

F Fabikan, H. P 49 Fediuk, M. P 58 Fediuk, M. P 61 Feizelmeier, H. F 04 Filipits, M. P 49 Fink-Neuboeck, N. P 58, P 61 Fischer, C. P 13 Fischer, J. R. P 50 Flicker, M. P 26, P 33, P 38 Flink, P. P 43, P 44, P 45 Foris, V. P 27, P 32, P 51 Forster, J. P 08 Frischer, T. P 40 Fritz, R. P 12 Fröhler, W. F 04 Froschauer, C. F 06 Frühauf, A. P 06 Funk, G. C. P 55 Funk, G.-C. P 48

G Gäbler, C. P 12 Geltner, C. P 33 Ghanim, B. P 15, P 16, P 21, P 22 Gitter, T. P 42 Gloeckl, R. P 56, P 57 Glogner, C. P 35 Glueck, O. P 35 Goerzer, I. P 62 Graeter, T. P 50 Grasl, M. A. P 24 Grusch, M. P 03, P 14 Gungl, A. P 15

H

ÖGIM

Abele, C. P 24 Adler, S. P 56 Aigner, C. P 05, P 30, P 34, P 35, P 46, P 47 Ambrosch, G. P 24, P 33 AMIG study group P 33 Amrein, K. P 10, P 29, P 31 Ankersmit, H. J. P 02, P 12 Ankersmit, J. P 30 Arnitz, R. P 18 Arns, B-M. P 48 Arns, M. P 33, P 38 Asadi, S. P 24 Aubell, K. F 08 Auer, W. P 26, P 63 Augustin, F. P 33 Avian, A. P 32 Avian, A. P 51 Awender, L. P 08

de Boer, M. F 08 Debek, E. P 07 Decker, S. P 50 DeJonge, R. P 08 Demel, U. F 08 Demmer, J. F 05 Denk-Linnert, D. P 36 Derntl, E. P 28 Didcock, J. P 12 Doberer, D. P 26 Dome, B. P 03, P 14 Dong, Y. P 33, P 34, P 38 Dorr, A. P 52 Douschan, P P 01, P 32 Douschan, P. P 51 Duller, M. P 24

Haas, V. P 50 Hacker, P. P 02 Hackner, K. F 09 Hahn, I. P 28 Haider, C. P 46 Handzhiev, S. P 33 Hannig, J. P 17, P 60 Harris, A. L. P 11 Hartl, S. P 04 Hasanovic, M. P 08 Haselwanter, E. F 11 Hasenhüttl, N. P 33 Hegedus, B. P 03, P 14 Heinzelmann, I. P 56 Hernler, T. P 33 Hesse, C. P 51 Hilberg, F. P 03 Hirzoiu, V. F 01 Hochmair, M. P 48, P 49 Hoda, M. A. P 03, P 14, P 33, P 34, P 38 Hoetzenecker, A. P 05 Hoetzenecker, K. P 35, P 36, P 47 Hoffmann, J. P 21 Holzer, P. P 16 Holzer, S. P 48, P 49 Horak, F. P 28 Hrzenjak, A. P 11, P 13 Hubner, M. F 13 Humenberger, M. F 05 Husemann, K. P 53

ÖGP

A

J JJain, P. P 16, P 22 Jaksch, P. P 05, P 46, P 47, P 62 Jamnig, H. F 11 Jamnig, H. P 33 Janik, S. P 02, P 12, P 30 Jerrentrup, A. P 56 Jeschek, B. P 63

K Kähler, C. P 26 Kaiser, B. P 04 Kapfhammer, I. P 48 Kaufmann, E. P 26 Kemmetinger, V. P 08 Kenn, K. P 56, P 57 Kerbl, R. F 08 Kirchbacher, K. P 33, P 48 Klade, S. P 26, P 43, P 44, P 45 Klepetko, W. F 07, P 02, P 03, P 05, P 12, P 14, P 15, P 16, P 21, P 22, P 30, P 33, P 34, P 35, P 36, P 38, P 41, P 46, P47, P 62 Klikovits, T. F 07, P 03, P 14, P 33, P 34, P 38 Kliman, J. P 12 Kneussl, M. F 13, P 26, P 33 Köfeler, H. C. P 11 Kohlhaeufl, M. P 53 Kohlmaier, B. F 08 Koller, M. P 12

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

837

ÖGP

ÖGIM

abstracts Autorenverzeichnis Koller-Herzog, U. F 01 Konstantiniuk, A. P 10 Korger, M. P 49 Kovacs, G. P 01, P 09, P 27, P 32, P 51 Kqiku, X. P 51 Krajc, T. P 39 Kreczy, A. F 11 Kropfmüller, R. F 05 Kruesmann, P. P 20 Krüsmann, P. P 06 Kühteubl, G. F 01 Kuhtin, O. P 50 Kupis, W. P 07 Kwapiszewska, G. P 15, P 16, P 19, P 21

L Lachmann, M. F 01 Lackner, H. F 08 Lambers, C. P 46, P 62 Lamprecht, B. F 05, P 04, P 26, P 42, P 43, P 44, P 45 Lang, B. F 04, P 26 Lang, E. P 14 Lang, G. P 05, P 30, P 34, P 46 Langfort, R. P 07 Laszlo, V. P 03, P 14 Leitgeb, M. C. P 24 Leithner, K. P 11, P 13 Leonhard, M. P 36 Lichtenschopf, A. F12 Lindenmann, J. P 58, P 61 Lins, F. P 26 List, S. P 28 Lobschat, V. P 08 Löffler-Ragg, J. P 26

M Maass, M. P 18 Maass, V. P 18 Machan, B. P 33 Macinkovic, J. P 08 Maria, K.-L. F 10 Marsh, L. M. P 15, P 16, P 19, P 21 Marsh, L. P 22 Marth, K. P 26 Marzluf, B. A. P 39 Matilla, J. P 34, P 46 Matilla, J. R. P 30, P 41 Meredith, A. P 22 Messner, J. P 26 Mikes, R. P 26 Mittendorfer, I. P 20 Mitterbauer, A. P 05, P 47 Mitterer, M. P 08 Mlczoch-Czerny, M.-T. F 13 Mohn-Staudner, A. P 48, P 49 Mori, C. P 40 Moritz, K. P 26 Moser, B. P 02, P 12, P 30, P 41 Müllauer, L. P 02 Müller, C. P 08 Müller, M. R. P 39 Muraköszy, G. P 46 Muraközy, G. P 62

Papp, R. P 22 Patocka, K. F 03 Payer, C. P 01, P 27 Pfleger, A. F 08, P 59 Pienn, M. P 01, P 09, P 27 Pirker, C. P 49 Pohl, W. F 03, P 26, P 33, P 38 Polachova, J. P 33 Poplawska-Wisniewska, B. P 07 Popp, W. P 54 Popper, H. P 33 Porsch, P. P 33 Prause, G. P 37 Pretsch, I. F12 Prosch, H. P 46 Puchhammer-Stöckl, E. P 62 Puelacher, C. P 06, P 20

Schiefer, A. P 02 Schillab, L. P 05, P 47 Schinko, H. P 43, P 44, P 45 Schmidt, R. P 55 Schnedl, C. P 29 Schneeberger, T. P 56, P 57 Schneider-Stickler, B. P 36 Schönfelder, M. P 04 Schuch, A. F 03 Schulz, H. P 53 Schwarz, S. P 36, P 47 Schweiger, T. P 35, P 36 Schwinger, W. F 08 Sczepanski, B. P 57 Seebacher, G. P 50 Seidel, M. F 08 Seitz, T. P 62 Seiwald, G. P 52 Setinek, U. P 48, P 49 Siekmeier, R. P 17, P 60 Singer, F. P 53 Slama, A. P 05, P 47 Smolle-Juettner, F. M. P 58 Sorantin, E. F 08 Soti, L. P 28 Sotoudeh, M. P 28 Sovinz, P. F 08 Spary, A. P 52 Speiser, M. P 33 Sperl, D. F 08 Spitzer, F. P 61 Stacher, E. P 21 Steidle-Kloc, E. P 04 Stein, M. F 11 Stepan, V. P 63 Stockhammer, P. P 33, P 34, P 38 Stollberger, R. P 09 Strenger, V. F 08 Striessnig, A. P 58, P 61 Stroedter, L. P 59 Studnicka, M. F 07, F 12 Studnicka, M. P 04, P 26, P 33 Studnicka-Benke, A. F 12 Szpechcinski, A. P 07

Q

T

Quehenberger, F. P 13

Taghavi, S. P 05, P 30, P 34 Tang, B. P 22 Thurner, U. P 28 Tichatschek, B. P 28 Till, H. F 08 Tiringer, K. P 40 Trockenbacher, C. P 33 Trötzmüller, M. P 11

N Nagaraj, C. P 22 Nagl, M. P 18 Nagy, B. P 22 Neuberger, M. P 08, P 25 Neunhäuserer, D. P 04 Niebauer, J. P 04 Niederseer, D. P 04 Nikolowsky, C. P 35 Novak, B. P 28

O Olschewski, A. P 01, P 09, P 11, P 13, P 15, P 16, P 19, P 21, P 22, P 27, P 32, P 51 Olschewski, H. P 01, P 09, P 11, P 13, P 19, P 21, P 27, P 32, P 33 Olschewski, H. P 51 Orlowski, T. P 07 Oswald, S. P 29 Ozsvar, J. P 03

P

R Rappold, J. F 01 Riegler, W. F 09 Roesner, I. P 36 Roos, D. F 08 Roszkowski-Sliz, K. P 07 Rowhani, M. P 26 Rozsas, A. P 14 Rudelstorfer, G. F12 Rudzinski, P. P 07

S Schadelbauer, E. P 31 Schäfers, H. J. P 50 Schenk, P. F 01, P 33, P 38

838   Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie

U Ulreich, R. P 59 Urban, Ch. F 08 Urschler, M. P 01, P 27

V Valipour, A. P 24, P 48 Varga, A. F 09

13

abstracts Autorenverzeichnis

W

Z Zacharasiewicz, A. P 26, P 40 Zajic, P. P 37 Zaleska, J. P 07 Zobel, G. P 59 Zöchbauer, S. P 33 Zounek, E. P 28

ÖGP

Wagner, C. P 28

Wandschneider, W. P 33 Wantke, F. P 26 Waseda, Y. P 46 Weiss, G. P 04, P 18 Windhager, R. F 07 Winterkamp, S. P 57 Wohlkoenig, C. P 13 Wonisch, S. P 33 vWygrecka, M. P 15

ÖGIM

Veres, J. F 09 Vinatzer, P. F 04 Voganjac, D. P 29 Vukicevic, B. P 28

13

Jahrestagung 2015 der Österreichischen Gesellschaft für Pneumologie  

839